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Although tyrosine kinase inhibitors (TKIs) such as imatinib have transformed chronic
myelogenous leukemia (CML) into a chronic condition, these therapies are not curative in
the majority of cases. Most patients must continue TKI therapy indefinitely, a requirement
that is both expensive and that compromises a patient’s quality of life. While TKIs are
known to reduce leukemic cells’ proliferative capacity and to induce apoptosis, their effects on
leukemic stem cells, the immune system, and the microenvironment are not fully understood.
A more complete understanding of their global therapeutic effects would help us to identify
any limitations of TKI monotherapy and to address these issues through novel combination
therapies.
Mathematical models are a complementary tool to experimental and clinical data that
can provide valuable insights into the underlying mechanisms of TKI therapy. Previous
modeling efforts have focused on CML patients who show biphasic and triphasic exponential
declines in BCR-ABL ratio during therapy. However, our patient data indicates that many
patients treated with TKIs show fluctuations in BCR-ABL ratio yet are able to achieve
durable remissions. To investigate these fluctuations, we construct a mathematical model
that integrates CML with a patient’s autologous immune response to the disease. In our
model, we define an immune window, which is an intermediate range of leukemic concen-
trations that lead to an effective immune response against CML. While small leukemic con-
centrations provide insufficient stimulus, large leukemic concentrations actively suppress a
patient’s immune system, thus limiting it’s ability to respond. Our patient data and modeling
results suggest that at diagnosis, a patient’s high leukemic concentration is able to suppress
their immune system. TKI therapy drives the leukemic population into the immune window,
allowing the patient’s immune cells to expand and eventually mount an efficient response
against the residual CML. This response drives the leukemic population below the immune
window, causing the immune population to contract and allowing the leukemia to partially
recover. The leukemia eventually reenters the immune window, thus stimulating a sequence
of weaker immune responses as the two populations approach equilibrium.
We hypothesize that a patient’s autologous immune response to CML may explain
the fluctuations in BCR-ABL ratio that are regularly seen during TKI therapy. These
fluctuations may serve as a signature of a patient’s individual immune response to CML. By
applying our modeling framework to patient data, we are able to construct an immune profile
that can then be used to propose patient-specific combination therapies aimed at further
reducing a patient’s leukemic burden. Our characterization of a patient’s anti-leukemia
immune response may be especially valuable in the study of drug resistance, treatment
cessation, and combination therapy.
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Chapter 1: Introduction
The goal of this dissertation is to develop and apply mathematical models to study
chronic myelogenous leukemia (CML). We take an interdisciplinary approach that combines
modeling with patient data, to study various aspects of the dynamics of CML and its treat-
ment. The biological background presented in Chapter 1 provides the foundation of these
models.
1.1 Introduction to CML
Hematopoiesis is a complex and tightly regulated process that maintains our body’s
blood supply, producing between 1011 and 1012 new blood cells per day. All of these cells are
derived from a single type of cell, the hematopoietic stem cells (HSCs). Each day, a small
subset of these cells differentiates and expands down the blood cell hierarchy in order to
produce the various types of mature blood cells. This process is heavily regulated in order
to ensure an appropriate balance of red blood cells, white blood cells, and platelets.
Leukemia is a type of cancer that occurs when a few mutated blood cells escape the
normal regulations of hematopoiesis. This type of cancer generally originates in the bone
marrow and eventually results in significantly elevated white blood cell counts. Leukemia can
be further classified as acute or chronic and as myeloid or lymphocytic based on the maturity
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and type of the leukemic cells. In this dissertation, we focus on chronic myeloid leukemia
(CML), a myeloproliferative disorder that accounts for about 20% of leukemias in adults.
CML occurs primarily in adults, with a median age of diagnosis of 65 years. A majority
of cases of CML is initiated by the formation of the BCR-ABL fusion oncogene, which
encodes for a constitutively active tyrosine kinase, that allows these cells to proliferate more
rapidly than their healthy counterparts and independently of external regulations. Without
treatment, CML patients typically progress from the chronic phase to the accelerated phase,
and finally to blast crisis, which is similar to acute leukemia and leads to metastasis, organ
failure, and death.
Introduced in the late 1990s, tyrosine kinase inhibitors (TKIs), such as imatinib (IM),
dasatinib, and nilotinib, have revolutionized the treatment of CML. These targeted therapies
work via competitive inhibition, by binding to the adenosine triphosphate (ATP)-binding site
of ABL tyrosine kinases, thus preventing these proteins from switching into their active form.
Because of their specificity, TKIs are able to target leukemic cells, while healthy cells are
left mostly intact. TKI therapy produces hematological and cytogenetic remissions in most
patients [34, 73]. Beyond these levels of remission, a patient’s response is determined on a
molecular level based on their BCR-ABL ratio, a blood measurement that represents the ratio
of BCR-ABL transcript to a control transcript, either BCR, ABL, or GUS. Many patients
achieve a major molecular response (MMR), or a 3-log decrease in BCR-ABL ratio, with
some even reaching MMR4 (4-log decrease), MMR4.5 (a 4.5-log decrease), or undetectable
minimal residual disease (UMRD) (undetectable by RQ-PCR, or a measured ratio of zero,
which generally corresponds to at least a 5-log decrease) [38]. Reaching UMRD may indicate
leukemia elimination in some cases, but often small concentrations of leukemic cells can be
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detected using more sensitive tests [86]. Still, TKIs have transformed CML into a chronic
condition, with patients’ life expectancies comparable to those of their healthy counterparts.
Despite their success, it is unclear whether TKIs alone can be curative, and as a result
patients typically continue TKI therapy indefinitely, a requirement that is both expensive and
compromises their quality of life. A more complete understanding of their global therapeutic
effect may lead to improved therapy schedules that would further reduce or eliminate any
residual leukemia. While TKIs are known to decrease leukemic cell proliferation [4, 41] and
increase apoptosis [24], other effects, such as their impact on the immune cell population
or on the microenvironment, may also play a significant role. Gallipoli et al. [29] and Rea
et al. [80] found that quiescent leukemic stem cells (LSCs) are insensitive to TKIs, which
suggests that ‘cure’ in the sense of elimination of the leukemic burden may not be possible
with TKIs alone. This finding is further supported by the fact that many patients in long-
term remission continue to harbor small residual leukemic loads even after many years of
therapy [86]. However, leukemia eradication may not be necessary to achieve an ‘operational
cure’ [31], in which a patient can stop therapy without relapsing, as evidenced in the various
treatment cessation trials, which will be discussed in Section 1.2. A better understanding
of TKIs would allow us to improve the way that these drugs are administered and also to
identify their limitations. If TKIs are incapable of curing most patients, then understanding
their mechanisms of action may inform our use of combination therapies.
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1.2 Treatment Cessation
Because of the success of TKI therapy for CML, many clinicians have shifted their ef-
forts toward the goal of achieving treatment-free remission (TFR). Currently, CML patients
continue TKI therapy indefinitely, regardless of whether they achieve long-term deep remis-
sions. However, treatment cessation is desirable for several reasons. First, although TKIs
are generally well-tolerated, these therapies, particularly second-generation TKIs, may have
significant side effects that can compromise a patient’s quality of life. Second, TKI therapy
is expensive, especially over many years. CML patients’ life expectancies are comparable
to their healthy counterparts’, and several decades of treatment can cost hundreds of thou-
sands of dollars per patient [87]. Given these quality of life and financial concerns, reducing
the necessary duration of therapy from a patient’s lifetime down to 5-10 years would be a
significant accomplishment.
Several clinical trials involving over 900 total patients [58] have been conducted in order
to evaluate the safety and efficacy of treatment cessation in patients who have responded
well to TKI therapy (that is, patients who have at least achieved a durable MMR4). Stop
Imatinib (STIM) [60] studied treatment cessation in 100 patients who had remained in
UMRD for at least two years. After stopping IM, patients’ BCR-ABL ratios were measured
once per month during the first year, every two months during the second year, and every
three months thereafter. Relapse was defined as two consecutive positive measurements
(loss of UMRD), where the second measurement represented a 1-log increase in BCR-ABL
ratio compared to the first measurement. In TWISTER [86], similar inclusion criteria were
used, and patients were monitored every month for the first year and every three months
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thereafter. In contrast to STIM, relapse was defined more strictly, as any two consecutive
positive measurements. Both trials found that about 60% of patients relapsed, mostly in the
first six months of treatment cessation. These patients then resumed IM therapy and were
generally able to re-achieve deep remissions. The remaining 40% achieved durable TFRs
that lasted for several years.
It is important to note, however, that the inclusion and relapse criteria may be un-
necessarily strict, thus excluding patients who would otherwise achieve TFR. ASTIM [88],
EUROSKI [92], and STIM2 [59] have explored alternative inclusion and relapse criteria.
Specifically, in ASTIM, patients were allowed to show occasional low-levels of BCR-ABL ex-
pression in the two years prior to treatment cessation. Relapse was defined as loss of MMR
(a ratio greater than 0.1%), a much weaker condition than loss of UMRD. Using the original
STIM relapse definition, 46% of patients were in TFR at two years, but with their new
definition, 64% remained in TFR. In the ongoing EUROSKI trial, patients were required to
have remained in MMR4 for the previous year. Preliminary results include a 6-month TFR
rate of 61.5%, which suggests that MMR4 may be sufficient. In a STIM2 interim report [59],
the authors observed a TFR rate of 61%, with median follow-up of 12 months. Interestingly,
one-third of TFR patients showed low-level fluctuations in BCR-ABL ratio but maintained
their MMR status. These trials suggest that with relaxed inclusion and relapse criteria, more
CML patients may be able to achieve TFR. The precise optimal set of requirements remains
to be determined.
Based on STIM and TWISTER, approximately 40% of CML patients treated with IM
will become eligible for treatment cessation, and about 10-15% will achieve long-term TFR.
If the definition of relapse is relaxed to loss of MMR, then this rate may increase to 20-25%
5
of all CML patients. It remains to be determined why some patients relapse within the first
six months of treatment cessation, while others achieve long-term TFR. Factors currently
being investigated include Sokal score, duration of IM therapy, the kinetics of response to
therapy, time to various levels of remission, duration of remission prior to cessation, prior
interferon-alpha (IFNα) therapy, and various immune cell markers. A summary of these
factors and remaining questions related to treatment cessation can be found in [58] and [87].
This analysis must also be extended to include patients treated with second-generation TKIs
nilotinib and dasatinib. A more complete understanding of the dynamics of TKI therapy
and treatment cessation would allow clinicians to identify the patients most likely to achieve
TFR.
1.3 The Immune System in CML
As previously mentioned, approximately 10-15% of patients treated with IM are ex-
pected to be able to achieve TFR. For the remaining patients, we would like to identify novel
strategies aimed at producing deeper remissions and improving their chances of successful
treatment cessation. One promising approach is to combine TKIs with an agent that affects
a patient’s autologous immune system.
There is compelling evidence that a patient’s immune response plays a significant role
in the dynamics of CML. In general, it is known that immune cells are capable of detecting
and eliminating cancer cells [71]. The cancer immune surveillance theory states that our
immune systems are continuously recognizing and eliminating newly transformed cells, to
prevent them from developing into malignant cancers. Initially, the immune system destroys
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these cells until they are eliminated or an equilibrium is reached. In the latter case, a subset
of these genetically unstable cells may escape immune surveillance to produce a tumor.
Immunotherapy is a major goal of both immunology and cancer research because of the
ability of the immune system to target and eliminate abnormal cells while leaving healthy
cells intact.
Prior to TKIs, many CML patients were treated with either allogeneic bone marrow
transplants [46] or IFNα [96], both of whose success seem to partially depend on inducing an
immune response. Following an allogeneic transplant, donor lymphocytes mount a response
that reduces and may even eliminate the CML clone. Allogeneic bone marrow transplants
may be the only curative therapy for CML but is rarely used because of its toxicity [46].
IFNα works through a variety of mechanisms, including induction of apoptosis, inhibi-
tion of growth, suppression of angiogenesis, and activation of immune cells [96]. A patient’s
immune system may play an especially important role in this therapy. IFNα improves the de-
tection of leukemic cells by increasing expression of tumor-associated antigens and MHC class
I molecules [7]. Additionally, CD8+ T cells [33,69,101], natural killer (NK) cells [54,95], and
dendritic cells [25, 82] are activated by IFNα. T cells specific for an antigen called PR1 are
specifically associated with successful IFNα therapy [12,68, 69] and are able to identify and
eliminate CML progenitor cells [67]. IFNα is able to induce cytogenetic remission in some
patients. A few of these patients have even achieved TFR [57, 96], despite the persistence
of detectable levels of CML [15, 35]. Interestingly, PR1-specific T cells are associated with
continued remission following IFNα cessation [40], which suggests that a patient’s immune
system may help to control the residual CML in the absence of therapy.
Several combination therapies involving TKIs and IFNα are currently being investi-
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gated [32,72,78], in part, because of their complementary mechanisms of action. While TKIs
do not affect quiescent leukemic stem cells [29,80], IFNα has both direct and indirect effects
on the immature leukemic population. IFNα may drive quiescent leukemic stem cells into
the cell cycle [28,91], where they become exposed to the effects of TKIs. The immunostimu-
latory effects of IFNα may also help in the elimination of CML cells not directly affected by
TKIs. Thus, while TKIs remain the primary first-line therapy for CML and are responsible
for eliminating the majority of the CML burden, IFNα may assist in controlling residual
CML cells.
Initial results suggest that TKIs combined with IFNα produce improved rates of molec-
ular response during the first few years of treatment [72, 78]. However, in many cases, the
toxicity of IFNα limits its effectiveness, and long-term benefits remain to be evaluated.
The addition of IFNα may improve a patient’s chances of achieving TFR [60], although
the observed advantage is not statistically significant, possibly due to small sample size. A
12-patient study found that while the two IM-only patients relapsed after stopping treat-
ment, six out of ten patients who had received a combination of IM and IFNα remained in
remission [89]. Despite these promising results, the toxicity of IFNα remains a significant
barrier, and further research is required to determine an optimal schedule for combining
these potentially complementary therapies.
The role of the immune system in the dynamics of CML is further supported by the
results of the IM cessation trials. Similar to the results of IFNα cessation studies, many pa-
tients who achieve TFR continue to express BCR-ABL DNA and mRNA [59,86]. Moreover,
in [14], patients still harbored BCR-ABL+ leukemic stem cells, despite having remained in
TFR for up to eight years. In these cases, since treatment did not completely eradicate the
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disease, some other mechanisms, such as the autologous immune system, must be preventing
this residual cancer population from expanding. The hypothesis that the immune system
controls the residual leukemic burden during TFR is further supported by the association
of TFR with prior IFNα therapy and the activity and presence of various immune popula-
tions. Specifically, several independent groups [39, 66, 74, 81] have observed that higher NK
cell count and functionality are associated with TFR. Additionally, Usuki et al. [102] found
higher memory CD8+ T cell concentrations and lower näıve CD8+ T cell concentrations in
patients who remained in TFR. A recent and promising 2015 study [11] shows that higher
concentrations of CD86+ dendritic cells are associated with relapse. Moreover, the authors
proposed a specific mechanism driving this phenomenon, namely, that CD86+ dendritic cells
interact with the CTLA-4 inhibitory receptor of T cells, which impedes T cells that would
otherwise participate in the body’s anti-leukemia immune response. Together, these findings
suggest that a patient’s autologous immune system may play a critical role in the future of
CML treatment, by providing biomarkers that guide clinical decisions, and by serving as an
additional therapeutic option to complement TKIs.
1.4 Outline of Thesis
The remainder of this dissertation is organized as follows. In Chapter 2, we present
an overview of the recent contributions of mathematical modeling groups to the study of
leukemia and lymphoma. Although our list is not exhaustive, it does provide a representation
of the types of contributions mathematicians can make to understanding these diseases. At
the end of the chapter, we focus on the models of Michor et al. [65], Kim et al. [43], and
9
Roeder et al. [85] and their applications to CML. These three models serve as a starting
point for our own mathematical modeling efforts.
In Chapter 3, we revisit the model of Roeder et al. [85], which we modify in order to
produce a model that more accurately reflects the biology of CML. We incorporate asym-
metric division, a variable lifetime for precursor cells, and feedback from mature cells into
the model. We present an implementation of this model as a system of difference equations,
followed by numerical simulations and a discussion of our results.
We present our own mathematical model of CML and the autologous immune system
in Chapter 4. We use this model to study the role of the immune system during IM therapy,
by applying it to patient data. A detailed analysis of this model is presented in Chapter 5,
followed by additional applications and extensions in Chapter 6. Finally, we conclude with
discussion of our work and future directions in Chapter 7.
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Chapter 2: Mathematical Models of Leukemia and Lymphoma
2.1 Motivation
Recently, there has been significant effort in the mathematical community aimed at
developing quantitative tools for studying leukemia and lymphoma. Mathematical models
complement clinical and experimental data and can be used to identify underlying mecha-
nisms driving an observed phenomenon, or to determine a quantity that is not experimentally
accessible. In a clinical setting, mathematical modeling can be applied to evaluate and im-
prove the scheduling of an existing therapy or to propose novel drug combinations.
Mathematicians, clinicians, and experimentalists have complementary skill sets and
perspectives that, when combined, can lead to significant improvements in patient care and
wellbeing. Leukemia and lymphoma research can benefit greatly from a collaborative and
interdisciplinary approach that allows each group to utilize the others’ expertise. Mathe-
maticians depend on clinicians’ and experimentalists’ understanding of a disease’s biology
in order to produce a realistic mathematical representation, and on their data in order to
validate their resulting models. Likewise, mathematical modeling provides an inexpensive
and efficient setting for preliminary testing of hypotheses before they reach the clinical and
experimental phase. Additionally, these models can guide experimental design and identify
critical parameters that should be measured. Ultimately, a research environment in which
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ideas and data are shared across disciplines will lead to more rapid discoveries that will
improve our ability to treat leukemia and lymphoma.
2.2 Summary of Mathematical Models
We begin with an overview of the recent contributions of mathematicians to the study
of leukemia and lymphoma. While the focus of this dissertation is CML specifically, these
works as a whole provide valuable insight into the clinical questions that mathematicians
can help to answer and some of the tools available to study these diseases. Although this
summary is not exhaustive, it does describe the contributions of many modeling groups to
the study of hematopoiesis, cancer genesis, therapy, and drug resistance. The rest of Section
2.2 was published in [20].
2.2.1 Hematopoiesis
Hematopoiesis is the process by which our body creates new blood cells. Mathematical
models of hematopoiesis provide a framework for mathematicians to study cancer genesis and
treatment strategies. Hematopoiesis can be modeled as a system of discrete maturity stages
starting with hematopoietic stem cells (HSCs) and ending with mature blood cells. Within
each stage, a balance between self-renewal and differentiation must be achieved. When a cell
divides, each daughter cell remains in its current compartment with a certain probability,
referred to as the renewal fraction, or differentiates and enters the next stage. This complex
and well-regulated process produces more than 1011 cells per day in order to maintain the
equilibrium levels of cells in the erythroid, lymphocyte, and myelocyte lines.
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Despite the complexity of hematopoiesis, several simple ordinary differential equation
(ODE) models have provided insight into the process. Michor et al. [65] divide blood cells
into four categories based on maturity - stem, progenitor, differentiated, and terminally
differentiated - and represent each by a single ODE. Healthy cells and cancer cells are as-
sumed to both progress through these differentiation stages, differing only in their rates of
differentiation and their ability to compete for resources.
Marciniak-Czochra et al. [61] also model hematopoiesis with a system of ODEs but
incorporate feedback inhibition via cytokines. It is known that environmental signals, such as
granulocyte colony-stimulating factor (G-CSF) [79] and erythropoietin [93], play a significant
role in regulating hematopoiesis [83]. In order to explore these regulatory mechanisms and,
specifically, their role in the rapid recovery of the mature blood cell population following
chemotherapy [45], the authors in [61] implement feedback inhibition from mature cells
that affects proliferation rates and/or renewal fractions of the less mature compartments.
This feedback is assumed to take the form of a single cytokine, such as G-CSF. When the
population of mature blood cells is large, the cytokine is consumed by these cells. When
the population of mature blood cells declines, the cytokine becomes more abundant, and
its presence triggers an increase in proliferation, an increase in renewal fraction, or both.
Numerical simulations suggest that regulation of renewal fractions alone leads to a more
rapid regeneration of the mature blood cells than does regulation of proliferation rates alone,
although combining the two leads to slightly faster recovery [61]. This model has also been
applied to studying the dynamics of leukemogenesis [94].
By incorporating time delays or accounting for spatial or age heterogeneity, more com-
plex models have been constructed in order to better capture the biology of the system. Time
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delays have been added to account for events such as cell divisions (for instance [1], [2]) and
the interactions between cancer and immune cells (for instance [43]). In [2], Adimy and
Crauste present three delay differential equation (DDE) models of cycling and quiescent
HSCs, with constant, distributed, and state-dependent delays. These delays represent the
time to complete one cell division. The system with distributed delays is derived from an
age-structured partial differential equation (PDE) in [1]. All three models have been applied
to studying periodic hematological diseases, which are characterized by oscillations in vari-
ous blood cell populations. It is concluded that although all three models produce periodic
solutions, the nature of the oscillations depends on the type of delay [2].
To explore oscillations that occur in multiple cell lines simultaneously, Colijn and
Mackey [21] combine constant DDEs representing HSCs, leukocytes, erythrocytes, and platelets.
This model includes more biological detail than those mentioned earlier, in that it replaces
the generic mature cell compartment with three different cell lines. The model is later applied
to cyclical neutropenia and G-CSF therapy [55].
In general, deterministic ODE and DDE models, like the ones presented so far, can
serve as good approximations of the average behavior of a system when the populations
are large. However, when considering small cell populations, stochasticity plays a key role
in the emerging dynamics. In [52], larger populations of mature cells are represented by
ODEs, while a stochastic model is used for the smaller populations of less mature cells.
Using a bivariate Markov process and its deterministic approximation, Chrobak et al. [16]
model the competition between healthy and precursor T-cell lymphoma cells, for a survival
stimulus. Cancer T cells are assumed to be more competitive and able to accept a wider
variety of stimuli. Simulations show that healthy T cells with more specific receptors survive
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longer than healthy T cells with less specific receptors, while cancer T cells, despite their
lack of specificity, are able to out-compete normal cells. To study drug resistance, branching
processes [53, 100] and birth-death processes [47, 49] with mutations have been applied to
calculate mutation probabilities and sizes of mutant clones at the time of cancer diagno-
sis. Stochastic models are especially useful when considering cancer genesis and resistance
mutations, as both processes start from a single cell.
In contrast to the previous population-based models, the agent-based model (ABM) of
Roeder et al. [85] treats each individual cell as an autonomous agent. The model considers
quiescent and cycling stem cells, progenitors, and mature cells. Each stem cell is character-
ized by an affinity variable, which represents its tendency to either cycle or remain quiescent.
Though ABMs retain valuable information about individual cells and their interactions, they
are very computationally demanding, and simulations involving a realistic number of cells
may not be feasible. To address this limitation, Kim et al. [44] reduce the Roeder model [85]
to systems of difference equations, while Kim et al. [42] and Roeder et al. [84] reduce the
model to a system of PDEs . Although some detail is lost in these reductions, both systems
can be used to quickly capture quantities of interest, such as the steady state distribution
of stem cells, with a realistic number of cells, as computation time does not depend on the
total number of cells.
Once these models have been parameterized and validated using experimental and
clinical data, they serve as useful tools for studying cancer treatment and drug resistance.
The models mentioned above have been applied to several diseases within the leukemia and
lymphoma families, including chronic myeloid leukemia (CML) [26, 30, 36, 43, 52, 65, 85, 97],
acute myeloid leukemia (AML) [1], T-cell lymphoma [16], and periodic hematological diseases
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[2, 21, 55].
2.2.2 The Dynamics of Treatment
One of the main goals of mathematical modeling of cancer is to improve treatment,
either by optimizing the way existing therapies are being administered, or by motivating novel
therapies. The optimal timing and dosage schedule remains an open question for many drugs
used to treat leukemia and lymphoma. Mathematical models have been utilized to investigate
treatment strategies, by considering, for instance, impulse versus continuous doses [30] as well
as the number of drugs to be used and their order [49,53,85]. Using sensitivity analysis and
numerical simulation, the dependence of a treatment outcome on specific model parameters
can be determined. Mathematical models can be applied to interpret experimental or clinical
data, or to evaluate a treatment strategy before it is tested in an experimental or clinical
setting.
Models of a single cell are useful for studying intracellular drug accumulation and con-
centrations of substances involved in cell fate decisions. In [77], intracellular and extracellular
concentrations of methotrexate (MTX), a treatment for acute lymphoblastic leukemia (ALL),
are modeled. In vivo measurements indicate that levels of intracellular MTX are greater in
leukemia B cells than in T cells. Simulations show that increasing the dose can only par-
tially compensate for the lower levels of intracellular MTX in T cells. It is hypothesized that
extending the infusion time would lead to greater MTX accumulations in leukemia T cells
and may enhance the effectiveness of the therapy [77]. A follow-up study [76] that compares
infusion times of four and twenty-four hours, in a clinical trial and with an extended MTX
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model that includes the drug’s effects on the folate pathway, supports this hypothesis.
Alarcon et al. [3] take a similar modeling approach to attempt to understand the
factors that determine the fate of lymphoma B cells during antibody treatment. Treatment
of lymphoma B cells with a specific antibody causes either apoptosis or quiescence. In
order to determine how to induce apoptosis in these B cells, an ODE model of intracellular
substances involved in cell fate decisions is developed. The modeling results suggest that
Myc plays a crucial role in cell fate decision of lymphoma B cells during antibody therapy.
A significant amount of attention has been given to modeling the treatment of CML.
Although we briefly cover some of these studies here, a more detailed description of these
models and their applications can be found in Section 2.3. These models have been applied to
investigate the underlying mechanisms of action of TKIs, which can then be used to identify
any limitations of these drugs. Several groups [52, 85, 99] have argued that IM affects all
leukemic cells and therefore may be able to cure patients after many years of treatment.
Others [26, 65] claim that certain subsets of leukemic cells are protected from the effects of
IM, and therefore a residual population of leukemia will remain indefinitely. These models
have also been applied to treatment cessation [36,97] and combination therapy [30,43].
2.2.3 Drug Resistance
Drug resistance remains a major challenge in leukemia and lymphoma therapy. Mathe-
matical models can be used to assess a patient’s risk of relapse upon diagnosis and to identify
strategies that minimize the probability of treatment failure.
Panetta et al. [75] conduct an experiment in which ALL T cells, of varying drug re-
17
sistance, are treated with mercaptopurine (MP), and cell cycle distributions and apoptosis
rates are measured. Using this data, they construct a mathematical model of the cell cycle
and apoptosis during MP treatment. The model divides cells into normally cycling cells;
cells that are cycling with thioguanine nucleotides (TGNs), a byproduct of MP, incorpo-
rated in their DNA and RNA; apoptotic cells; and necrotic cells. Interestingly, the model
parameterizations suggests that the rate of TGN incorporation is greater in resistant cells
than in sensitive cells. However, this difference is overcome by the higher rates of entry into
apoptosis found for the sensitive cell line compared to the resistant lines. This result suggests
that although the drug is able to incorporate itself into the cancer cells’ DNA, resistance is
explained by an inability of resistant cells to detect damaged TGN-incorporated DNA [75].
Using branching processes [53, 100] and birth-death processes with mutations [47, 49],
several groups have sought to quantify the probability of resistance and the size and diversity
of resistant clones, at the time of diagnosis. In both types of models, cancer initiates from
a single cell, with a birth rate, death rate, and a small probability of mutation per division.
Mutations can lead to several different resistance clones, each with its own growth kinetics.
The time of diagnosis is estimated by the time at which the cancer population reaches a
certain size. Using both simulation and analysis techniques, the aforementioned quantities
can be determined.
Tomasetti and Levy [100] construct a model of cancer stem cells in which the cells
may divide in one of three ways. A stem cell may divide into two stem cells (symmetric
renewal), differentiate into two progenitor cells (symmetric differentiation), or divide asym-
metrically into one stem cell and one progenitor cell. By incorporating data on the relapse
rate of patients that are treated with IM [34], it is concluded that cancer stem cells tend
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to symmetrically renew, as opposed to their healthy counterparts that predominantly divide
asymmetrically [100]. In a later paper [99], Tomasetti argues that, based on modeling re-
sults [100] and clinical data [60], IM affects leukemic stem cells the same way it affects all
leukemic cells, by decreasing their proliferation rates.
Leder et al. [53] and Komarova et al. [47, 49] use their models to determine when
combination therapy can be administered to minimize the chance of resistance mutations.
In [53], the authors calculate that if a patient is diagnosed at an early stage of cancer, then
there is only a 12% chance of having a resistance mutation. However, when diagnosed at a late
stage, the risk increases, and multiple mutations become possible [53]. Their modeling results
demonstrate the importance of early detection and also suggest that combination therapy
is advantageous when the cancer is detected at a late stage. Komarova and Wodarz [47]
create a mathematical framework to study resistance to targeted therapies. It is found
that the combination of three drugs should prevent resistance in the treatment of CML.
Komarova et al. [49] later consider specific resistance mutations to TKI treatment of CML.
They evaluate the effectiveness of combinations of IM, dasatinib, and nilotinib. Most of
the known resistance point mutations confer resistance to only one of the three, but the
T315I mutation causes resistance to all three [4]. It is concluded that two-drug combination
therapies can increase the probability of treatment success, but adding a third drug does not



























  d1  d2  


















Figure 2.1: The Michor model divides healthy cells (x) and leukemic cells (y)
into stem cells (x0, y0), progenitors (x1, y1), differentiated cells (x2, y2), and
terminally differentiated cells (x3, y3). Healthy cells xi and leukemic cells yi are
assumed to have the same death rates di for each compartment i, but to differ
in their stem cell growth rates r and their differentiation rates a, b, and c. The
parameters in red (ry, ay, and by) are those affected by IM therapy.
2.3 Models of CML
We now shift our focus to mathematical models of CML, specifically the Michor model
[65], the DDE model of Kim et al. [43], and the Roeder model [85]. For each, we will present
the details of each model and then discuss their applications. Ultimately, these three models
serve as a basis from which we constructed our own CML model (see Chapter 4).
2.3.1 The Michor Model
The Michor model [65] is an ODE model that divides both healthy cells (x) and
leukemic cells (y) into stem cells (x0, y0), progenitors (x1, y1), differentiated cells (x2, y2),
and terminally differentiated cells (x3, y3). These populations are described by the following
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system of equations.
ẋ0 = (rxϕ− d0)x0, (2.1a)
ẋ1 = axx0 − d1x1, (2.1b)
ẋ2 = bxx1 − d2x2, (2.1c)
ẋ3 = cxx2 − d3x3, (2.1d)
ẏ0 = (ryψ − d0)y0, (2.2a)
ẏ1 = ayy0 − d1y1, (2.2b)
ẏ2 = byy1 − d2y2, (2.2c)
ẏ3 = cyy2 − d3y3. (2.2d)
In the equations above, r is the maximum division rate of stem cells, and p is the sensitivity
of each population to crowding. The parameters a, b, and c are differentiation and expansion
rates of the stem cells, precursors, and differentiated cells. Lastly the {di} are the death
rates of each compartment. The terms ϕ = 1/(1 + px(x0 + y0), and ψ = 1/(1 + py(x0 + y0))
incorporate competition between healthy and leukemic stem cells. The parameters px and
py represent each population’s sensitivity to crowding. Although these terms are not in the
original model [65], they are introduced in [26] and are included in future works [97, 98]. A
diagram representing this model can be found in Figure 2.1
Leukemic cells are assumed to have a greater stem cell proliferation rate (ry > rx), a
greater stem cell differentiation rate (ay > ax), and to be less sensitive to crowding (py < px)
than healthy cells. Healthy and leukemic cells are assigned the same death rates. IM therapy
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decreases the proliferative capacity of leukemic cells, by decreasing the parameters ry, ay,







By analyzing patients’ initial response to IM therapy, Michor et al. [65] find that many
patients show a biphasic exponential decline in BCR-ABL ratio. In their model, the first,
sharper decline is explained by the decreased proliferative capacity of differentiated cells
(a′y < ay), which causes both the differentiated and terminally differentiated populations to
shrink. After 3-6 months, these populations reach an equilibrium relative to the progenitor
compartment. During months 6-12, there is a second, slower exponential decline that is
explained by a similar effect on progenitors (b′y < by), until they reach an equilibrium with
the stem cell population. The parameters a′y and b
′
y are calculate based averages of their
patient data, and are assumed to be the same for all patients. The slopes of these two
declines are interpreted as the death rates of the progenitors (d1) and differentiated cells
(d2), which are allowed to vary between patients.
In their initial fits, the authors assume that IM has no effect on leukemic stem cells (that
is, r′y = ry). The leukemic stem cell population continues to grow during therapy. Eventually,
all simulated patients relapse, a result that does not accurately represent the long-term
effects of IM seen in most patients. However, their initial data only includes the first year
of IM therapy, so their fits are largely unaffected by this assumption. In a later analysis
of patients’ long-term responses over many years of IM therapy [98], these assumptions are
adjusted to allow IM therapy to also affects leukemic stem cells, by decreasing their growth
rate (ry < r
′
y). Some patients show a triphasic exponential decline in leukemic load. The
authors hypothesize that the third decline may represent an effect on a less mature leukemic
population, such as the leukemic stem cells. In [26], it is suggested that a successful therapy
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must target leukemic stem cells in order to eliminate the leukemic clone, a result which
motivates the question of whether IM alone may be curative.
In [97], Tang et al. attempt to understand the contrasting results of the STIM trials
[60]. They first sought to determine whether TFR indicates cure in some patients, or whether
these patients continue to harbor small residual leukemic clones. However, both cure and
non-cure statistical models were in agreement with the STIM data, suggesting that a longer
follow-up time was necessary to make any conclusions. By parameterizing the Michor model
based on STIM survival curves, it is found that the leukemic population has significantly
slower growth kinetics after treatment than before treatment. This result suggests that
selection pressures during IM therapy lead to different subsets of the heterogeneous leukemic
population surviving, which in part explains the disparate outcomes of the trial. The author
notes that this selection effect may act in combination with suppression of the leukemia by
the immune system, crowding, or the microenvironment.
2.3.2 DDE Model of CML and the Immune System
In [43], Kim et al. present the following DDE model of CML and the immune system
in order to study the anti-leukemia immune response during IM therapy.
ẏ0 = (ry − d0)y0 − qCp(C, T )y0, (2.3a)
ẏ1 = ayy0 − d1y1 − qCp(C, T )y1, (2.3b)
ẏ2 = byy1 − d2y2 − qCp(C, T )y2, (2.3c)
ẏ3 = cyy2 − d3y3 − qCp(C, T )y3, (2.3d)
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Figure 2.2: The DDE model of Kim et al. [43] considers leukemic stem cells y0,
progenitors y1, differentiated cells y2, and terminally differentiated cells y3, which
are all modeled as in the original ODE model of Michor et al. [65] An additional
T cell compartment T is described by a DDE, where the delay nτ accounts for
the time to complete n cell divisions, each of which requires time τ , following
stimulation by a leukemic cell.
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where
Cnτ = C(t− nτ),
Tnτ = T (t− nτ),





In this model, which is depicted in Figure 2.2, the variables {yi} represent leukemic stem
cells, progenitors, differentiated cells, and terminally differentiated cells, and an additional
variable T is introduced that represents anti-leukemia T cells. As in the Michor model (see
Equations (2.1a)-(2.2d)), ry is the growth rate of leukemic stem cells, which are assumed to
grow exponentially in the absence of an immune response. The parameters ay, by, and cy are
differentiation rates, while {di} are natural death rates. The last terms p0qCe−cnCkTyi in the
leukemic cell equations represent an anti-leukemia immune response. The rate of interaction
between T cells T and each leukemic subpopulation yi is described by a mass-action term
kTyi with coefficient k. The constant p0 is the probability that a T cell engages, while qC
is the probability that the leukemic cell dies because of that engagement. This probability
p0qC is decreased by a factor e
−cnC in order to incorporate immune suppression by the total
leukemic population C =
∑3
i=0 yi.
Lastly, T cells are assumed to have a constant source term sT and a constant death rate
dT . The third term on the right side represents T cells that engage leukemic cells and commit
to n rounds of cell division. The last term represents the population increase due to immune
cells that committed to division at a time nτ in the past, where τ is the time to complete one
cell division. The variables Cnτ and Tnτ are the leukemic and T cell concentrations at time
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t− nτ . A T cell survives the encounter with the leukemic cell with probability qT , and if it
survives, it produces 2n new T cells. We note that the precise interactions between leukemic
and immune cells are not known, and so there are several alternate ways of representing
these interactions, as shown in [50] and [70].
Without an immune response, and assuming no effect of IM on leukemic stem cells,
the leukemic stem cells continue to grow exponentially. The model therefore predicts that
all patients will relapse after about 3 years of therapy. On the other hand, simulations of
this model with an immune response produce long-term remissions that are in agreement
with patient data. These contrasting outcomes suggest that a patient’s immune system may
play a critical role during IM therapy.
The authors therefore sought to characterize patients’ individual immune responses to
CML. They fit their model to individual patient data by choosing patient-specific values of
sT , dT , cn, n, and y0(0). They define an optimal load zone for leukemic cells that maximizes
the anti-leukemia immune response. This zone coincides with the range of leukemic loads
C where the rate of immunostimulation p0ke
−cnC exceeds the T cell death rate dT and
is therefore patient-specific, as it depends on the parameters cn and dT . Based on their
modeling results and data measuring patients’ immune responses during IM therapy, they
hypothesize that IM may drive the leukemia below the optimal load zone. As a result, after
an initially strong immune response, the T cells contract, allowing the leukemic population
to survive and partially recover. This result suggest that carefully-timed patient-specific
vaccines may help to maintain a patient’s strong immune response in order to further reduce
or even eradicate the leukemic population.
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2.3.3 The Roeder Model
In this section, which is taken from our publication [19], we provide a brief overview
of the Roeder model [85]. The Roeder model is an ABM that considers hematopoietic cells
in three compartments: stem cells (STC), proliferating precursor cells (P), and mature cells
(M). Stem cells are either quiescent, denoted by A, or cycling, denoted by Ω. Let A(t) and
Ω(t) represent the total number of quiescent and cycling stem cells at time t. Each individual
stem cell is characterized by an affinity variable a(t) ∈ [amin, amax] which determines the
probability that the cell will be quiescent or cycling. At each time step, which represents
one hour, a quiescent stem cell will enter the cell cycle with probability ω, and a cycling









Thus, cells with affinity a(t) close to amax tend to remain or become quiescent, while cells









) + ν4, (2.6)
fα(A(t)) =
1





) + µ4. (2.7)
Both functions, fω and fα, are decreasing sigmoidal functions whose shapes depend on the
parameters νi and µi. The parameters Nω and Nα are scaling factors for Ω(t) and A(t).
Given the values of fω at Ω(t) = 0, Nω/2, Nω, and ∞, we can compute the coefficients νi as
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follows:
ν1 = (h1h3 − h22)/(h1 + h3 − 2h2),
ν2 = h1 − ν1,
ν3 = log((h3 − ν1)/ν2),
ν4 = fω(∞),
where
h1 = 1/(fω(0)− fω(∞)),
h2 = 1/(fω(Nω/2)− fω(∞)),
h3 = 1/(fω(Nω)− fω(∞)).
A similar set of formulas can be used to determine the parameters µi of fα. These functions
are constructed so that cells that are in the less-populated compartment are less likely to
move.
Quiescent cells that remain quiescent during a time step increase their affinity by a
factor of r, until they reach the maximum affinity amax. Cycling cells that continue to cycle
during a time step decrease their affinity by a factor of d, until they reach the minimum
affinity amin. In other words, cells that remain in A or Ω become more likely to stay in A or
Ω in the future.
Cycling cells are also characterized by a cell cycle counter c(t), which represents their
place in the cell cycle. In [85], the cell cycle lasts 49 hours, so c(t) ∈ {0, 1, ..., 48}. The first
32 hours represent the G1 phase, where cells grow and can transition to quiescence. Cells
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Figure 2.3: A diagram for the Roeder model. (1) At each time step, quiescent
stem cells enter the cell cycle with probability ω, while cycling cells in G1 become
quiescent with probability α. Quiescent stem cells that remain quiescent during
a time step increase their affinity by a factor of r, up to a maximum value of
amax. Cycling stem cells that continue to cycle decrease their affinity by a factor
of d. (2) Cycling stem cells progress through G1, S, G2, and M. The cell cycle
counter c(t) ∈ {0, 1, ..., 48} indicates the cell’s phase in the cell cycle. Stem cells
enter the cell cycle at hour c(t) = 32. At hour c(t) = 48, the cell divides, and
its daughter cells reset their cell cycle counters to c(t) = 0. (3) A cycling stem
cell whose affinity reaches amin differentiates into a precursor cell, which lives
for 20 days and divides once per day. (4) In the last division, precursor cells
differentiate into mature cells, which do not divide and die after 8 days.
cell cycle. After the cell divides (c(t) = 48), each daughter cell reenters G1 (c(t) = 0) and
becomes an uncommitted cycling cell that may transition to quiescence. Quiescent cells that
enter the cell cycle have their cell cycle counter initialized to c(t) = 32, which means that
they commit to at least one division. Stem cells that reach affinity a(t) = amin differentiate
into precursor cells. Precursors (P ) live for a fixed amount of time and undergo a fixed
number of divisions. They then differentiate into mature cells (M), which do not divide and
die after a fixed amount of time. Figure 2.3 summarizes the Roeder model.
Both healthy (Ph-) and cancer cells (Ph+) cells differentiate through the maturity
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stages discussed above. Ph- cells and Ph+ cells compete at the stem cell level through the
functions fω and fα, whose inputs are the total number of cycling cells and quiescent cells,
respectively. Ph+ cells differ from Ph- cells in their transition functions fω and fα. It is
assumed that Ph+ stem cells are more likely to transition between quiescence and cycling
and that the probability of a quiescent Ph+ stem cell transitioning to cycling is only slightly
affected by the current number of cycling stem cells. Cancer genesis is characterized by a
long latency period of 5 to 7 years, in which Ph+ and Ph- populations coexist. Without
treatment, Ph+ cells are eventually able to out-compete Ph- cells and take over the system.
Treatment with IM is assumed to have two effects on Ph+ stem cells while not directly
affecting Ph- cells. First, all cycling Ph+ stem cells are killed at a rate rdeg. In addition,
all cycling Ph+ stem cells become IM-affected with probability rinh. Once a Ph+ stem cell
becomes IM-affected, its transition function fω is decreased significantly, making it much
less likely for quiescent Ph+ stem cells to enter the cell cycle. Note that there is no direct
action of IM on quiescent Ph+ stem cells.
The effect of the treatment is evaluated by monitoring levels of BCR-ABL fusion tran-
script in the blood. These levels are reported relative to an endogenous control transcript,
BCR or ABL, in order to normalize the BCR-ABL measurements. This relative value, known
as the BCR-ABL ratio, is estimated in [85] by
BCR-ABL ratio =
100× (# of mature Ph+ cells)
2× (# of mature Ph- cells) + (# of mature Ph+ cells)
. (2.8)
The contributions of stem cells and precursors to this ratio are negligible because these
populations are small relative to the mature cells, and the mature cells are the dominant
population in the blood. In each healthy Ph- cell, there are two copies of the control gene,
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while Ph+ cells are assumed to possess one copy of the BCR-ABL fusion gene and one copy
of the control gene. Thus, BCR-ABL transcript levels should be proportional to the number
of mature Ph+ cells, while the control transcript levels should be proportional to twice the
number of mature Ph- cells plus the number of mature Ph+ cells. This quantity is multiplied
by 100 so that it represents a percentage.
In simulations, treatment leads to a biphasic exponential decline in BCR-ABL levels,
with a rapid first decline followed by a slower second decline. However, small populations of
Ph+ cells persist over many years of treatment, and cessation of treatment generally leads
to a rapid relapse.
The Roeder model is later applied to study the combination of TKIs and IFNα [30].
In their modeling framework, IFNα is assumed to stimulate quiescent cancer cells to enter
the cell cycle, where they are more likely to be affected by IM. It is shown that pulsed IFNα
with continuous IM is nearly as effective as administering both drugs continuously, but with
significantly less toxicity. Moreover, since the initial response to IM alone is very strong, the
authors suggest that pulsed IFNα should be started after 9-12 months of IM-only therapy.
Simulations of this combination therapy suggest that the addition of IFNα may reduce the
time to CML eradication from 25 years with IM alone down to as few as three years.
Using patient-specific data, the Roeder model is used in [36] to determine which pa-
tients can be safely taken off IM without relapsing. The slopes of each patient’s biphasic
decline are used to estimate the parameters rdeg and fω (which is constant for leukemic cells
during treatment). Treatment cessation is then simulated in order to determine whether a
patient would relapse or remain in remission. Their model predicts that 14% of patients
will be cured after 15 years of therapy while an additional 16% will remain in TFR for at
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least two years despite harboring residual leukemic populations. The authors provide model-
based and model-independent criteria for selecting the best treatment cessation candidates.
Together with other clinical markers, their criteria may be used to improve the number of
patients who achieve TFR.
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Chapter 3: Incorporating Asymmetric Stem Cell Division into the Roeder
Model
3.1 Overview
In this chapter, we propose several modifications to the Roeder model [85] (described
in Section 2.3.3), in order to construct a model that more closely represents hematopoiesis.
Specifically, we incorporate asymmetric division of stem cells and precursors, allow precursors
to live a variable amount of time before maturing, and introduce feedback inhibition from
mature cells to stem cells and precursors. These modifications result in more accurate
simulations of cancer genesis and treatment. We begin by presenting a reduction of the
Roeder model to a system of difference equations. Then, we discuss the additional biological
details that we incorporate into the model, which we then incorporate into the system of
difference equations. Lastly, we present results of numerical simulations and discuss the
implications of our findings. The content of the remainder of this chapter was previously
published in [19].
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3.2 Reducing the Agent-Based Model to a System of Difference Equations
Although the Roeder model has the advantage of being able to capture the dynamics
of cell-cell interactions, simulations with a realistic number of agents is computationally very
expensive. In the simulations in [85], the number of cells is down-scaled to 1/10 of normal
patient values, resulting in approximately 105 stem cells. Even with this reduction in the
number of agents, a simulation of 20 years requires approximately 175,000 steps for each of
the 105 agents (Precursors and mature cells can be represented as populations, so the total
number of agents is the total number of stem cells.) To address this limitation, the Roeder
model is reduced to a system of PDEs in [42] and [84] and a system of difference equations
in [44]. In this section we follow [44] and provide a brief summary of the system of difference
equations. A modified version of this system is used for the numerical simulations that we
present in Section 3.4.
In order to decrease the number of variables, Kim et al. [44] discretize the affinity state
space. In [85], d = 1.05 and r = 1.1, so log(d) = ρ = 0.0488 ≈ log(r)/2. By setting d = eρ
and r = e2ρ, any cell whose initial affinity is of the form a(t) = e−kρ for an integer k will
continue to have this form. Since 0.002 ≤ a(t) ≤ 1, k is restricted to 0 ≤ k ≤ 127. Because
of the negative in the exponent, the maximum affinity corresponds to the minimum k value,
and the minimum affinity corresponds to the maximum k value. More importantly, though,
with these new values of r and d, it is no longer necessary to track individual agents. Rather,
we can group stem cells into populations whose affinity a(t) = e−kρ, for each of the finitely
many k values.
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Define Ak(t) and Ωk,c(t) as follows:
Ak(t) = Number of cells in A at time t with log a(t) = −kρ (3.1)
Gk,c(t) = Number of cells in Ω at time t with log a(t) = −kρ and c(t) = c (3.2)
As mentioned earlier, k ∈ {0, ..., 127}, and c ∈ {0, ..., 48}. Given this discretization, the
Roeder model is represented by the following system of difference equations:
Ak(t+ 1) =

(A0(t)−B0(t)) + (A1(t)−B1(t)) + (A2(t)−B2(t)), k = 0
(Ak+2(t)−Bk+2(t)) +
∑31
c=0Ψk,c(t), k = 1 . . . 125∑31




B0(t), k = 0, c = 32
2Ωk−1,48(t), k > 0, c = 0
Ωk−1,c−1(t)−Ψk−1,c−1(t), k > 0, c = 1, . . . , 31
(Ωk−1,31(t)−Ψk−1,31(t)) + Bk(t), k > 0, c = 32
Ωk−1,c−1(t), k > 0, c = 33, . . . , 48
0 otherwise
(3.4)
The terms Bk represents the number of cells that leave Ak and enter the cycling compartment
Ωk,32. Ψk,c is the number of cells that leave Ωk,c and enter the quiescent compartment Ak.












, c = 0, ..., 31, (3.6)
where, Ω(t) =
∑
k,c Ωk,c(t) and A(t) =
∑
k Ak(t) are the total number of cycling and qui-
escent stem cells, and the functions ω and α are defined in Equations (2.4) and (2.5). In
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our simulations, we replace these stochastic variables with their expected value and allow
populations to be continuous variables.
At each time step, a quiescent cell may remain quiescent or enter the cell cycle. Cells
that remain quiescent increase their affinity by a factor of r, which translates to a decrease
in k by two. Equation (3.3) describes the number of quiescent cells in each compartment, at
time t + 1. The first line (k = 0) represents the number of cells entering A0, namely those
cells previously in A0, A1, or A2, that remain quiescent. In the second line (k = 1, ..., 125),
cells previously in Ak+2 that remain quiescent enter Ak. The summation term is the number
of cycling cells in Ωk,c that become quiescent. The sum is over c ∈ {0, ..., 31} because only
cells in G1 can become quiescent. Lastly, when k = 126 or k = 127, there are no quiescent
cells with k > 127 to feed these compartments. Therefore, the only cells entering these
compartment are cycling cells that become quiescent.
On the other hand, cycling cells that continue to cycle decrease their affinity by a
factor of d, which translates to an increase in k by one. At each step, the cell cycle counter
also increases by one. The cycling cells are described by Equation (3.4). The first line
(k = 0, c = 32) represents cells that have maximum affinity who are entering the S phase of
the cell cycle. Since there are no cycling cells with greater affinity, the only cells entering
this compartment are quiescent cells that have just entered the cell cycle. The second line
(k > 0, c = 0) represents cells that have just completed the cell cycle. The constant 2
represents division into two daughter cells, whose cell cycle counters are reset to c(t) = 0.
The third line (k > 0, c = 1, ..., 31) represents cycling cells in the G1 phase. The right hand
side is the number of cycling cells in the (k − 1)st compartment that continue to cycle. The
beginning of the S phase, marked by c(t) = 32, is where transitioning quiescent cells enter
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the cell cycle. The fourth line (k > 0, c = 32) is similar to the third, with an additional term
for the quiescent cells that begin cycling. The fifth line (k > 0, c = 33, ..., 48) represents cells
in S, G2, and M. Because these cells have committed to division, they all progress to the
next step in the cell cycle and increase their k value by one, until division. All other cycling
cell compartments are zero at all times.
When a cycling cell’s affinity reaches its minimum, corresponding to k taking its maxi-
mum value of 127, the cell differentiates into a precursor cell. The precursor cell divides once
per day for twenty days (480 hours). Upon the last division, both daughter cells differentiate
into mature cells, which live for another eight days without dividing, and then die. The






c=0Ψ127,c(t), j = 0





2P479(t), j = 0
Mj−1(t), otherwise
(3.8)
Here, Pj(t) is the number of cells that have been precursors for j hours, where j ∈ {0, ..., 479}.
Mj(t) is the number of cells that have been mature for j hours, where j ∈ {0, ..., 191}. In
Equation (3.7), the first line on the right hand side represents cycling stem cells that reach
minimum affinity (k = 127), continue to cycle, and become precursors. The second line
accounts for the division of precursor cells, which occurs every 24 hours. For all other
values of j, cells increase their age j by one per time step. In Equation (3.8), precursor
cells completing their final division become mature, which is the first line. The second line
represents the fact that mature cells continue to age without dividing.
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As in the Roeder model, cancer genesis is simulated by initializing a single Ph+ stem
cell into the Ph- cell steady state. Both populations are described by the system of difference
equations (Equations (3.3), (3.4), (3.7), (3.8)). The two populations compete at the stem
cell level and differ in their transition functions fω and fα.
In simulating treatment, we divide the Ph+ population into two categories: those
that are not affected by IM, which we denote Ph+/R, and those that are, which we denote
Ph+/I. These two Ph+ populations differ in their transition function fω, with the Ph+/I
stem cells being much less likely to transition from quiescence to cycling. At the beginning of
treatment, all Ph+ cells are not IM-affected. The effects of treatment are assumed to occur
at the beginning of every time step. For each k and c, let Ω
+/R
k,c (t) be the number of cycling
Ph+/R cells, and let Ω
+/I
k,c (t) be the number of Ph+/I cells. Each cell in Ω
+/R
k,c will become
IM-affected with probability rinh. The number of cells in Ω
+/R
k,c that becomes IM-affected at
that time step is given by Ω
+/I,new
k,c (t) ∼ Bin(Ω
+/R
k,c (t), rinh). We set
Ω
+/R







k,c (t) := Ω
+/I
k,c (t) + Ω
+/I,new
k,c (t). (3.10)
We additionally assume that all cycling Ph+ cells will apoptose with probability rdeg.
We therefore remove these cells from the Ph+ populations at the beginning of each time step,
by subtracting them from Equations (3.9) and (3.10). In our simulations, we choose to make
the effects of IM deterministic by setting the number of cells that become IM-affected and
apoptose to the expected values rather than taking them from their binomial distributions.
Once the values of Ωk,c(t) are updated, all three populations (Ph-, Ph+/R, Ph-/I) evolve
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Figure 3.1: A diagram of the modified Roeder model. (1) Stem cell transitions
between quiescence and the cell cycle are unchanged. The affinity variable is
updated in the same way as in the original model. (2) Cycling stem cells progress
through G1, S, G2, and M. Stem cells enter the cell cycle at hour c(t) = 32. (3)
At hour c(t) = 48, the cell divides, and each daughter cell will remain a stem cell
with probability aSTC(t) and will differentiate into a precursor with probability
1 − aSTC(t). Precursor cells symmetrically renew ten times. For all subsequent
divisions, up to a total of thirty divisions, the daughter cells will remain precursors
with probability aP (t) and will differentiate into mature cells with probability
1− aP (t). (4) On the last division, both precursor cells differentiate into mature
cells. Mature cells provide feedback, marked by dashed lines, that affects the
renewal fractions aSTC(t) and aP (t) of the stem and precursor cells. After 8
days, mature cells die.
3.3 Modifications to the Roeder Model
In this section we propose several modifications to the Roeder model [85]. Our model
is summarized in Figure 3.1. First, we consider three types of stem cell division:
1. Asymmetric division, in which one daughter cell remains a stem cell and the other
differentiates into a precursor cell
2. Symmetric differentiation, in which both daughter cells differentiate into precursors
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3. Symmetric renewal, in which both daughter cells remain stem cells.
In the Roeder model, all dividing stem cells symmetrically renew. Differentiation into
precursor cells is not tied to a division event, and stem cells whose affinity reaches amin
instantaneously transform into precursor cells. Thus, the affinity variable controls both cell
cycle transitions and differentiation.
By incorporating these three types of cell division, each with probability a′, b′, and c′,
where a′+b′+c′ = 1, we provide a mechanism for differentiation that is independent of affinity,
while still allowing a cell’s affinity to control transitions between quiescence and cycling.
Several other modeling groups have represented differentiation in this way, including [61]
and [100]. Moreover, in [100], it is suggested that cancer stem cells tend to symmetrically
renew, while healthy stem cells tend to divide asymmetrically. By associating differentiation
with a cell division, it becomes possible to implement this hypothesis in the model.
Secondly, we allow precursor cells to divide a variable number of times before they
differentiate into mature cells. To implement this, we allow precursors to go through the
same three types of divisions as stem cells. Precursors can divide between 10 and 30 times
before differentiating into mature cells. This range is centered around 20 divisions, which
is assumed for all precursor cells in [85]. The lower bound to the number of divisions
enforces a minimum number of divisions before maturation, and the upper bound prevents
any precursor cells from living forever.
Lastly, it is known that hematopoiesis is a very closely regulated process that is affected
by many different signals and cytokines [64]. For instance, G-CSF is known to play a
significant role in granulopoiesis [64,79]. Motivated by [61], we implement feedback inhibition
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from mature cells that affects less mature cells (precursors and stem cells). Consider a
cytokine S(t) that is produced at a constant rate α, degraded at a constant rate d, and is
consumed by mature cells at a rate β. Then
dS
dt
= α− dS − βSM, (3.11)
where M(t) is the number of mature cells. Since the cytokine dynamics occur on a faster
time scale than cell division, we may assume that the cytokine exists at its quasi-steady











This quantity represents the probability that a daughter cell of a stem cell will also
be a stem cell. In [61], feedback inhibition affects proliferation rates, renewal fractions, or
both, in the less mature compartments. It is found that regulation of self-renewal fractions is
essential for the system to be able to recover from events such as chemotherapy that deplete
the mature blood cell population. Therefore, we choose to focus on feedback inhibition that










Here, aSTC,max and aP,max define the maximum renewal fractions of the stem cell and pre-
cursors, respectively. As M(t) becomes smaller, the renewal fractions of both stem cells and
precursors increases, in order to expand both pools, which ultimately leads to an increase in
mature cells.
We incorporate these changes into the system of difference equations defined by Equa-
tions (3.3), (3.4), (3.7), and (3.8). These changes do not change the form of Equation (3.3).
Line 2 in Equation (3.4) is replaced by
Ωk,c(t+ 1) = 2aSTC(t)Ωk−1,48(t), 0 < k < 127, c = 0, (3.16)
in order to incorporate asymmetric division of stem cells. Each of the two daughter cells of
the dividing stem cell will remain a stem cell with probability aSTC(t). Note that instead
of choosing the number of daughter stem cells from a binomial distribution, we use the
expected value. All other lines in Equation (3.4) are unchanged, for 0 ≤ k < 127. However,
when k = 127, we must account for the fact that cycling cells with minimum affinity are no
longer differentiating into precursors but instead remain stem cells. Thus, when k = 127, we
replace Equation (3.4) with
Ω127,c(t+ 1) =

2aSTC(t)(Ω126,48(t) + Ω127,48(t)), c = 0∑127
k=126Ωk,c−1(t)−Ψk,c−1(t), c = 1 . . . 31∑127
k=126(Ωk,31(t)−Ψk,31(t)) +Bk(t), c = 32
Ω126,c−1(t) + Ω127,c−1(t), c = 33, . . . , 48
(3.17)
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k Ωk,48(t), j = 0
2Pj−1(t), j = 24, 48, 72, ..., 240
2aP (t)Pj−1(t), j = 264, 288, 312, ..., 696
Pj−1(t), otherwise
(3.18)
Since the precursors can now live for up to 30 days, j = 0, ..., 719. Line 1 in Equation (3.18)
represents new precursor cells. Stem cells differentiate into precursors during cell divisions,
each of which produces two daughter cells. Each daughter cell will become a precursor with
probability 1− aSTC(t). All progenitor cells divide every 24 hours. The first 10 divisions are
symmetric renewals, which is represented by line 2 in Equation (3.18). For each subsequent
division, up to a total of 30 divisions, daughter cells will remain precursors with probability
aP (t). For all other times, precursor cells age by one hour.
The mature cells are described by
Mj(t+ 1) =

2P719(t) + 2(1− aP (t))
∑29
d=11 P24d−1(t), j = 0
Mj−1(t), otherwise
(3.19)
The only difference from Equation (3.8) is when j = 0. This line represents the source
of mature cells. The first term of line 1 of Equation (3.19) represents precursors who are
completing their 30th division and must undergo symmetric differentiation. The second
term represents the contributions of all precursors who are completing their dth division,
where d = 11, ..., 29. For these divisions, each of the two daughter cells differentiates with
probability 1 − aP (t). We use this modified system of difference equations to produce the
simulations that are discussed in Section 3.4.
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3.4 Numerical Results
For our simulations, we use the system of difference equations in [44], modified to
incorporate the changes discussed in Section 3.3. For all parameters that are present in the
original Roeder model, we choose the same values given in [85]. In order to allow the stem
cell compartment to grow or shrink, we must set aSTC,max > 0.5. We choose aSTC,max = 0.52
and aP,max = 0.51. In determining the value of k, we observe that at steady state, the total
number of stem cells should be constant. In this model, this occurs when the renewal fraction
of the stem cells aSTC(t) = 0.5. Thus, if we want a steady-state solution with M(t) = M
′,





We set M ′ = 6.8246 · 1010 cells, which is the mature healthy cell steady state value in [44]
and apply Equation (3.20) to determine k.
Using these parameters, numerical simulations of healthy cells produce a shift in the
stem cell population toward their cycling state, when compared to the simulations in [44]
and [85]. This shift had to be addressed since it is known that the stem cells tend to be
quiescent [5]. In order to restore the quiescent stem cell population, we reduce the function
fω by a factor of 10, in comparison to the function used in the original Roeder model. In
other words, we reduce the probability that a quiescent stem cell will enter the cell cycle.
This modification restores the balance of stem cells, with 91% in quiescence at steady state.
The parameters, including this modification of fω, are given in Table 3.1.
In implementing carcinogenesis, as in [85], we introduce a single Ph+ stem cell into
the healthy cell population at its steady state. As mentioned previously, in [85], Ph- and
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Parameter Description Ph- Ph+/R, Ph+/I
amin Minimum value of affinity a 0.002 0.002
amax Maximum value of affinity a 1.0 1.0
ρ Affinity factor 0.0488 0.0488
d Differentiation coefficient eρ eρ
r Regeneration coefficient e2ρ e2ρ
τc Cell cycle duration 49 hours 49 hours
τS Duration of S phase 8 hours 8 hours




10-30 days 10-30 days
λm Lifespan of mature cells 8 days 8 days
τ̃c
Cell cycle of proliferating
precursors
24 hours 24 hours
fα(0) Transition characteristic for fα 0.5 1.0
fα(Nα/2) Transition characteristic for fα 0.45 0.9
fα(Nα) Transition characteristic for fα 0.05 0.058
fα(∞) Transition characteristic for fα 0.0 0.0
Nα Scaling factor 10
5 105
fω(0) Transition characteristic for fω 0.05 0.1, 0.00500
fω(Nω/2) Transition characteristic for fω 0.03 0.099, 0.00499
fω(Nω) Transition characteristic for fω 0.01 0.098, 0.00498
fω(∞) Transition characteristic for fω 0.0 0.096, 0.00496
Nω Scaling factor 10
5 105
aSTC,max








The steady state number of
mature cells
6.8246 · 1010 1.36492 · 1010
Table 3.1: Parameters for the simulations in Section 3.4. We replace the constant lifespan
λp = 20 days of precursors with a range of 10-30 days. Additionally, all parameters related to
fω are decreased by a factor of 10 compared with the values in [44], to restore the population
of quiescent stem cells. For all other parameters included in the original Roeder model,
we choose the same values given in [44]. The last three parameters arise because of our
modifications to the model. The parameter M ′ is used in Equation (3.20) to determine the
value of k.
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Figure 3.2: A simulation of cancer genesis. The solid line represents mature Ph-
cells, and the dashed line represents mature Ph+ cells.
Ph+ cells compete at the stem cell level. They differ in their transition functions fω and
fα. We decrease fω for both populations by a factor of 10, in order to maintain the same
relative difference between these functions for the Ph- and Ph+ cells. We additionally
assume that Ph- and Ph+ stem cells compete for cytokine, which is consumed by the mature
cells of both populations. We choose a smaller value of k for the Ph+ population, which
represents cancer’s decreased sensitivity to environmental signals. Specifically, we set kcancer
= khealthy/2.
Figure 3.2 shows a simulation of cancer genesis for the parameters values described
above. The simulation shows a long latency time during which Ph- (solid) and Ph+ (dashed)
cells coexist. The Ph+ population becomes greater than the Ph- population between years
5 and 6. These simulations show similar behavior to the simulations of cancer genesis in [44]
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and [85].
A simulation of a treatment is shown in Figure 3.3. The initial conditions are taken from
the end of the cancer simulation in Figure 3.2. The number of quiescent stem cells, number
of mature cells, and BCR-ABL ratio are displayed as functions of time. In comparison with
results from [44,85], we observe a much slower decline in the BCR-ABL ratio and the number
of cancer cells during treatment. This difference can be understood by considering the Ph+
stem cells. First, recall that quiescent Ph+ stem cells are assumed to be unaffected by IM.
These cells are only affected by IM if they enter the cell cycle. Thus, a decrease in the
transition rate of stem cells from quiescence to cycling results in quiescent Ph+ stem cells
that will remain quiescent for longer periods of time, during which they will remain protected
from IM. Figure 3.3(a) illustrates this phenomenon, as the number of quiescent Ph+ stem
cells decreases by less than one order and remains above 104, after 20 years of treatment.
As a result, the number of mature Ph+ cells, shown in Figure 3.3(b), remains above 107.
The BCR-ABL ratio, shown in Figure 3.3(c), decreases by about 3.5 orders. The simulated
patient achieves a MMR, or a 3-log decrease in BCR-ABL ratio, at year 4. However, MMR4
(a 4-log decrease in BCR-ABL ratio) and MMR5 (a 5-log decrease) are not achieved.
We consider varying the two treatment parameters, rdeg and rinh, in order to simulate
patients that achieve MMR4 and MMR5. We find that increasing rdeg, the rate at which IM
kills cycling Ph+ stem cells, results in an increase in the rate at which cancer is cleared, as
illustrated in Figure 3.4. By increasing rdeg, our simulated patient achieves MMR
4 (rdeg =
0.066 hour−1) and MMR5 (rdeg = 0.132 hour
−1).
On the other hand, rinh has a non-monotonic relationship with the rate of cancer
clearance. The parameter rinh describes the rate at which cycling Ph+ stem cells become IM-
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Figure 3.3: A simulation of treatment. (a) Quiescent stem cells. (b) Mature
cells. (c) BCR-ABL ratio. In Figures (a) and (b) Ph- cells are represented by
a solid line, Ph+ cells that are not affected by IM are represented by a dashed
line, and Ph+ cells that are affected by IM are represented by a dotted line.
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Figure 3.4: BCR-ABL ratio is plotted during treatment, for three different values
of rdeg: 0.033 hour
−1 (solid), 0.066 hour−1(dashed), and 0.132 hour−1 (dotted).
As rdeg increases, the BCR-ABL ratio declines more rapidly. For all three simu-
lations, rinh = 0.05 hour
−1.
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Figure 3.5: Number of quiescent Ph+ stem cells and BCR-ABL ratio dur-
ing treatment, for three different values of rinh: 0 hour
−1 (solid), 0.05 hour−1
(dashed), 0.1 hour−1 (dotted). (a) Quiescent Ph+ stem cells. (b) BCR-ABL ra-
tio. Initially, a higher value of rinh leads to faster cancer clearance, but later the
lower values of rinh become more favorable. For all three simulations, rdeg = 0.033
hour−1.
affected, meaning they become less likely to enter the cell cycle. Decreasing the transitions
of quiescent Ph+ stem cells to cycling has two contrasting effects. On one hand, Ph+ stem
cells are prevented from cycling, limiting the number of mature Ph+ cells. On the other
hand, these quiescent Ph+ stem cells cannot be eliminated from the stem cell population,
as IM does not kill non-cycling Ph+ stem cells.
For large rinh, the Ph+ population rapidly shifts toward these decreased transition
rates. As a result, initially the simulations show a sharper decline in mature Ph+ cells,
compared to simulations with smaller rinh values. However, Ph+ stem cells with IM-affected
transition rates remain quiescent for longer periods of time and are protected from the
degradation effect of IM. Eventually, the number of mature Ph+ cells for rinh large becomes
greater than the number of mature Ph+ cells for rinh smaller. Figure 3.5(b) shows the effects
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of treatment on mature Ph+ cells over time, for different values of rinh.
Figure 3.5(a) shows the number of quiescent Ph+ stem cells over time for different
values of rinh. Here, the relationship is more straight-forward. As rinh increases, Ph+ stem
cells become IM-affected more rapidly, and as a result, the number of quiescent Ph+ stem
cells increases.
3.5 Discussion of Modified Roeder Model Results
In this chapter we modified the Roeder model [85] by adding more biological detail.
Specifically, we incorporate asymmetric division of stem cells and precursors, allow precur-
sors to live for a variable amount of time before maturing, and add feedback inhibition
from mature cells that affects stem cells and precursors. A more accurate representation of
hematopoiesis can lead to more realistic simulations of CML genesis and treatment.
Parametrization of our model suggests that healthy stem cells transition between the
quiescent and proliferating compartments at rates that are lower than the rates obtained in
the original Roeder model. In the Roeder model, at healthy steady state, approximately 1
quiescent stem cell enters the cell cycle per 1000 quiescent stem cells per time step. Thus,
quiescent cells enter the cell cycle, on average, once per 1.4 months. In contrast, in our
simulations, 1 quiescent stem cell enters the cell cycle per 10,000 cells, which translates to
quiescent cells entering the cell cycle, on average, once every 14 months. This lower rate of
entry into the cell cycle by stem cells is supported by [56] and [90].
Lower stem cell transition rates have a significant effect on the results of IM therapy.
In our model, we assume that IM only affects cycling Ph+ cells. By decreasing the transition
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rates of Ph+ stem cells, quiescent Ph+ stem cells can better evade the effects of IM during
treatment. During 20 years of simulated treatment, we see an initial phase of a few months
when IM kills most cycling Ph+ stem cells. Once the cycling Ph+ population is depleted, the
majority of the remaining Ph+ stem cell population is quiescent and is therefore protected
from IM. What follows is a very slow decline in the number of quiescent Ph+ cells over time,
since only a few of these cells enter the cell cycle every hour. Our treatment simulations
indicate a much larger residual cancer population than those in [85]. These results suggest
that IM alone, acting through the implemented mechanisms, can never fully eradicate the
cancer population.
The Stop Imatinib trial [60] sought to determine whether patients who responded well
to IM therapy could be safely taken off treatment without relapsing. They found that while
61% of patients relapsed, 39% remained in remission for the duration of the two-year study.
It is possible that some of the patients in sustained remission had no Ph+ cells remaining
when they stopped IM. If this is the case, it may imply that there is an additional action
of IM that is not included in the model. Alternatively, patients that remain in sustained
remission after stopping IM may still harbor small populations of Ph+ cells. Remaining in
remission after stopping IM would then require some other mechanism (e.g. the immune
response) to control the Ph+ population and prevent it from expanding.
Still, the fact that many patients do relapse after being taken off IM motivates studying
methods by which IM therapy can be improved. Our results suggest that IM therapy may
greatly benefit from quiescent Ph+ stem cell activation. IFNα has been shown to activate
quiescent stem cells [28] and is therefore a strong candidate for combination therapy. A
detailed analysis of immunotherapy in this context is left for a future study.
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Chapter 4: The Role of the Autologous Immune System During Imatinib
Therapy
The majority of this chapter is taken from [17] and [18].
While TKIs have transformed chronic phase (CP) CML into a long-term survivable
and manageable condition, these drugs are not curative in the majority of cases. As a result,
patients need to continue therapy indefinitely, a requirement that is both expensive and
impairs their quality of life. Further study of the underlying mechanisms of action of TKIs
will elucidate whether this limitation is the result of a suboptimal therapy schedule (that is,
if changes in the timing and dosage might actually result in a curative therapy), or whether
TKIs alone are simply insufficient and combination therapy is necessary. Mathematical
modeling is a valuable and complementary tool to clinical data that can be used both to
investigate existing therapeutic strategies and to propose novel combinations.
Several mathematical modeling groups have studied various aspects of CML and TKI
therapy (see Chapter 2). Both Michor et al. [65] and Roeder et al. [85] observed that at the
beginning of IM therapy, leukemic loads exhibit an initial sharp exponential decline, followed
by a second, slower exponential decline. While Michor et al. argued that the biphasic
exponential decline is the result of decreased proliferative capacities of leukemic progenitors
and differentiated cells, Roeder et al. hypothesized that IM affects cycling leukemic stem
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cells while having no direct effect on quiescent cells.
Although both modeling frameworks capture some characteristic initial responses to
therapy, they do not include mechanisms that allow oscillations in the BCR-ABL/ABL ratio
to develop. While some patients’ leukemic loads continue to monotonically decline, resulting
in a triphasic exponential decline [98], our patient data indicates that the leukemic loads
of many responding patients exhibit fluctuations. These fluctuations do not necessarily
indicate relapse but appear to be an integral part of the response to TKI therapy. The
inability of these modeling frameworks to reproduce these fluctuations suggests that an
additional mechanism, not included in either model, plays a significant role in the dynamics
of TKI therapy. In order to address this limitation, we construct a mathematical model that
integrates CML and the autologous immune response.
4.1 Our Model of CML and the Autologous Immune System
We develop an ODE model of CML and the immune system, to study the dynamics
of IM therapy. Specifically, we seek to understand patients whose BCR-ABL ratios vary
non-monotonically during therapy.
Let y0, y1, and y2, and y3 represent the concentrations of quiescent leukemic stem







































































Figure 4.1: Mathematical model including the intervention of the autologous im-
mune system. In our model of CML and the immune response, we divide leukemic
cells into quiescent stem cells (y0), cycling stem cells (y1), and progenitors (y2),
and mature cells (y3). Stem cells transition between quiescence and cycling, and
some cycling stem cells differentiate into progenitors cells, which can further dif-
ferentiate into mature cells. Leukemic cells can die naturally at rates di or as
a result of an interaction with immune cells (z). Immune cells are supposed in
this disease to be supplied at a constant rate sz and to die at a rate dz. They
can also be stimulated by leukemic cells to divide to produce more immune cells.
Large leukemic populations are able to suppress the autologous immune system,
by limiting immune cell expansion and limiting immune effector cells’ ability to
kill cancer cells.
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z denote the concentration of immune cells. We consider the following system of ODEs.





























In Equations (4.1a) and (4.1b), a0 and b1 represent the transition rates of leukemic stem cells
from quiescence to cycling and cycling to quiescence, respectively. We assume logistic growth
of cycling stem cells, with growth rate r and carrying capacity K. Cycling stem cells die
naturally at a rate d1. In Equation (4.1c), the first term represents the differentiation of stem
cells into progenitors. The coefficient a1 is the product of the differentiation rate and the
amplification factor upon differentiation due to cell proliferation. Progenitors die naturally
at a rate d2. Equation (4.1d) is similar to Equation (4.1c), with differentiation rate a2 and
death rate d3. The last terms in Equations (4.1a)-(4.1d) represent the death of leukemic cells
caused by an immune response. The mass action term µyiz represents the killing of leukemic
cells by the immune system, where µ is the maximal rate (per immune cell) at which an
immune cell will engage and kill a leukemic cell. Equation (4.1e) represents the concentration
of autologous immune cells. The first term sz is a constant source term. Immune cells die
at a rate dz. The mass action term αy3z represents the expansion (proliferation) of the
immune cell pool in response to its leukemia stimulus, which occurs with maximal rate
per leukemic cell α. We include only the contributions of the mature leukemic cells y3 to
immune stimulation since they are a much larger population than the immature leukemic
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cells (ytotal ≈ y3).
Our model is based on the assumption that immunosuppression acts in two ways. First,
mature leukemic cells inhibit the expansion of immune cells. In Equation (4.1e), the immune
cell expansion term αy3z is divided by 1+ ϵy
2
3, where the constant ϵ determines the strength
of the immunosuppression. Second, mature leukemic cells are assumed to decrease the killing
capacity µ of activated immune cells, also by a factor of 1+ ϵy23. This effect is represented in
the last terms in Equations (4.1a)-(4.1d). This approach is similar to the one used in [43].
By implementing immunosuppression in this way, we encode an autologous immune response
that is effective only with intermediate levels of leukemic cells. When the leukemic load is
small, only a small number of immune cells is stimulated to respond. On the other hand,
although large leukemic loads provide a stronger stimulus, the leukemic cells are able to
suppress the efficacy of the immune system. Thus, the immune response will be negligible
when the leukemic load is either very small, at levels undetectable by the immune system,
or very large, at levels that overwhelm and suppress the immune system. A strong immune
response can occur only when the leukemic load y3 is at an intermediate level, within a range
[ymin, ymax] that we call the immune window. In our model, we define the immune window
as the range of y3 for which the rate of immune stimulation αy3
1+ϵy23
exceeds the death rate dz.
IM therapy may be used to drive the leukemic load into this immune window, allowing the
autologous immune system to assist the drug in the elimination of the leukemic cells. Our
model is summarized in Figure 4.1.
IM is known to block the kinase activity of the BCR-ABL protein, which results in
a significant decrease in the proliferation rates of the BCR-ABL+ leukemic cells [4, 41] and
apoptotic death [24]. However, we focus here on the effects of IM on proliferation and leave
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incorporation of other mechanisms to a future work. We implement IM therapy, starting at







. It is unknown how IM affect leukemic stem cells and whether
quiescent leukemic stem cells are affected at all, so we assume no direct effect of IM on these
populations. However, our model provides a framework for testing various mechanisms of
actions of IM, which we leave for a future work.
It is also unclear whether IM is capable of completely eliminating the leukemic cell
burden, or whether small residual populations will persist indefinitely. In our model, a
leukemic load of zero can only be approached asymptotically, so we define cure as a cancer
stem cell concentration less than 1.67 · 10−4 cells/mL, which corresponds to less than one
leukemic stem cell. We stop all simulations of the model whenever this is achieved.
4.2 Materials and Methods
A group of 104 patients with CML was monitored during IM therapy in the Centre
Hospitalier Lyon Sud. These patients were all treated with first-line IM 400 mg daily.
Patients’ BCR-ABL ratios were measured in the same laboratory according to the guidelines
of European LeukemiaNet, with the same techniques at diagnosis, months 3, 6, 9, and 12 of
therapy, and every 6 months thereafter; in order to limit variability, each measurement was
run in duplicate, and the two resulting measurements were averaged. Overall, the patients
had an average follow-up time of 62.76 months (range: 2.96 - 148.70), with an average of
12.69 measurements taken (range: 2 - 26). We excluded patients who changed TKIs for
safety reasons (n = 33) and patients whose disease progressed (n = 14), as we focused
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exclusively in this study on patients obtaining a residual disease on IM. Thus, a population
of 65 patients who responded well to IM remained for analysis.
BCR-ABL ratios were serially measured by quantitative RT-PCR in the peripheral
blood of patients in the same laboratory according to the European standards of European
Leukemia Net recommendations [6, 22] and expressed as a percentage on the International
Scale (IS) [37]. Each sampling was run in duplicate in order to reduce variability and
additionally run in parallel to the previous (frozen) sample from each patient in order to
exclude technical problems, at each time point (except diagnosis) for all patients. A two-fold
variation was considered as significant [8].
Our mathematical model (Equation (4.1)) divides leukemic cells into quiescent stem
cells (y0), cycling stem cells (y1), progenitors (y2), and mature cells (y3). We also represent
a single autologous immune cell population (z). For simplicity, we do not distinguish further
between immune subpopulations. Leukemia cells stimulate immune cells to proliferate at a
maximum rate α, while immune cells kill leukemia cells at a maximum rate µ. We incorporate
immunosuppression by inhibiting the proliferation of the immune cells as well as their action
on leukemic cells. Our model is summarized in Figure 4.1. A more thorough description of
the model is provided in Section 4.1.
As was previously discussed in Sections 1.1 and 2.3.3, the BCR-ABL ratio is a blood
measurement that quantifies the amount of BCR-ABL transcript relative to a control gene
transcript, in our case ABL. Each leukemic cell (y3) possesses the BCR-ABL gene and the
normal allele of ABL gene, while healthy cells (x) possess two alleles of the ABL gene.
Therefore, BCR-ABL transcripts are proportional to y3 (the immature leukemia cell popu-
lations are much smaller than the mature population and can be neglected), while control
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transcripts are approximately proportional to 2x+ y3. For simplicity, the number of healthy
cells (x) is assumed to be constant and is estimated based on the patient’s initial BCR-ABL





This equation is similar to Equation (2.8) used in [85], with an additional multiplication
factor β that accounts for differences in mRNA expression between BCR-ABL and the control
gene. We multiply by 100, in order to convert the ratio into a percentage when β = 1 and a
value between 0 and 100β otherwise.
4.3 Results
Many patients who otherwise respond well to therapy exhibit oscillations in their BCR-
ABL ratios. Of the 104 patients in our data set, only 15 showed monotonically decreasing
BCR-ABL ratios throughout therapy. Each of the remaining 89 patients showed increases in
BCR-ABL ratios in, on average, 28.82% of their measurements. Two representative patients
are shown in Figure 4.2. These fluctuations occurred in many patients who responded well
to IM therapy and did not have any adverse events. This lack of monotonicity in patients
who responded well to therapy motivated this study.
We applied our mathematical model, which is summarized in Figure 4.1, to the patient
data in order to study these oscillations. As previously mentioned, our model represents
leukemic cells of varying maturity and a single immune cell population. We applied Latin
hypercube sampling in order to determine the effect of the drug (a′1 and a
′
2) and the immune
parameters (µ, dz, α, and ϵ). The parameters dz, α, and ϵ determine the patient’s immune
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Figure 4.2: Oscillations of the BCR-ABL ratio in two representative patients.
During TKI therapy, a patient’s progress is monitored by measuring their BCR-
ABL ratio, which is a ratio of BCR-ABL mRNA expression to the expression
of a control gene, in this case ABL. Both patients shown above were treated
with standard IM 400 mg daily. During treatment, both patients show multiple
increases in BCR-ABL ratio without overt relapse. Here, dots represent clinical
data, and the dashed line approximates the detection threshold, or the lowest
detectable leukemia level. Dots along this line indicate measurements of zero,
meaning the leukemia was undetectable within the limits of the assay. These
figures correspond to patients 4 and 12 in Table 4.2.
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window [ymin, ymax], or the range of leukemia loads that will stimulate a strong immune
response. We define [ymin, ymax] by the range of y3 for which the level of immune stimulation
exceeds the death rate. For each patient, we selected the parameter set that minimizes
the squared log-distance between the patient data and the results of the model simulation
(sampled at the same time as the data). All other parameters were held constant across all
patients; their values can be found in Table 4.1. Figures 4.3 and 4.4 show representative fits
of our model to patient data. Keeping in mind that these fits are plotted on a logarithmic
scale, we see that our model is able to reproduce many patients’ dynamics during therapy.
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d1 Cycling stem cell death rate 0.00225 [43]
d2 Progenitor cell death rate 0.006 [43]
d3 Mature cell death rate 0.0375 [43]
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Table 4.1: Universal parameter estimates. This table
provides the values of the universal parameters. Cell
concentrations are in cells/mL. The initial values y0(0)+
y1(0) and y2(0) are chosen based on the initial number
of leukemic stem (2.5 · 105 cells) and precursor cells (108
cells) in [65], converted to cells/mL by assuming a blood
volume of 6 L. The value y3(0) is estimated in [23]. The
value z(0) is also based on [23], assuming a concentra-
tion of 6 · 105 cells/mL, of which about 1/5000 is spe-
cific to leukemia. Quiescent stem cells enter the cell cy-
cle infrequently [43], so we set a0 equal to 1/365 day−1.
The parameter b1 is set to 9a0 so that most stem cells in
our model are quiescent, which is in agreement with [56].
Thus, the two stem cell populations will approximately
have a 1:9 ratio, so we set y0(0) = 0.9(y0(0) + y1(0)) and
y1(0) = 0.1(y0(0) + y1(0)). The death rates d1, d2, and
d3 are set to those in [43]. The stem cell growth rate is
also based on the value in [43]. We increase the origi-
nal value (r = 0.008) by a factor of 10 to account for
the fact that only 10% of the stem cells in our model
contribute to growth, while all stem cells contribute to
growth in [43]. The parameters K, a1, and a2 are se-
lected so that the initial conditions represent a steady
state when the immune response is removed from the
model. (That is, y1(0) = K(r−d1)/r, y0(0) = b1y1(0)/a0,
y2(0) = a1y1(0)/d2, and y3(0) = a2y2(0)/d3.) We as-
sume that z(0) = sz/dz, so the value of dz determines sz.
Lastly, the adjustment factor β is selected based on the
maximum BCR-ABL ratio (269) in our data set.
The patient data and modeling results suggest that patients who respond well to IM
therapy go through three to four phases of tumor reduction. During the first few months,
there is a rapid exponential decline in BCR-ABL ratio. In our model, this effect is due
primarily to the action of the drug on the mature leukemic population. The immune response
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Figure 4.3: Fits of our mathematical model to six representative patients. The
base-10 log of the BCR-ABL ratio is plotted against time, in months. The dots
represent patient data, and the solid lines represent our simulations. Dashed
lines show the BCR-ABL ratios that correspond to the ends of immune window,
ymin and ymax. These figures correspond to patients 1-6 in Table 4.2.
64






























































































































Figure 4.4: Fits of our model to six additional patients. The base-10 log of the
BCR-ABL ratio is plotted against time, in months. Dots represent patient data,
and the solid lines represent our simulations. Dashed lines show the BCR-ABL
ratios that correspond to the ends of immune window, ymin and ymax. Dotted
lines approximate the minimum leukemic level that is detectable by RT-PCR.
Dots along this line represent zero measurements, meaning CML cells were not
detected. These figures correspond to patients 7-12 in Table 4.2.
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is negligible at this stage because the large leukemic load suppresses the immune system.
Beginning around month six, there is a second, slower exponential decline in BCR-ABL ratio.
In some patients, the second phase is a plateau in BCR-ABL ratio rather than a decline (see
Figure 4.3(d)). The location of this plateau is determined primarily by the direct effects of
IM on the leukemic cell population (parameters inh1 and inh2). This biphasic exponential
decline has been previously observed in [65] and [85]. A few patients show a triphasic
exponential decline (Figures 4.4(b)-4.4(d)), which was discussed in [98]. The duration of the
biphasic or triphasic decline can vary significantly between patients, from the first two years
(Figures 4.3(a), 4.3(c), 4.3(d), and 4.4(f)) to several years of therapy (Figures 4.4(b)-4.4(d)).
After this period of monotonic decline, many patients’ leukemic loads begin to vary
non-monotonically. These fluctuations are often preceded by a sudden sharp decline in the
leukemic population, as illustrated in Figures 4.3(f), 4.4(b), and 4.4(d)-4.4(f). If this effect
is sufficiently strong, the leukemic stem cell population may be driven to less than one cell,
which we interpret as cure in our model. Otherwise, the leukemic population is able to par-
tially recover. Several oscillations in both the leukemic and immune cell populations follow,
with their amplitudes decreasing over time as the populations approach an equilibrium, as
seen in Figure 4.5.
Patient-specific parameter values are given in Table 4.2 and are summarized in Table
4.3. Of the six parameters varied, the fits seem to be most sensitive to inh1 and inh2,
followed by ymin and ymax. The parameters dz and µ seem to be less important. This is not
surprising, as inh1 and inh2 determine the effect of the drug, and ymin and ymax determine
at what point the autologous immune response becomes significant. Scatter plots depicting
parameter sensitivities for a representative patient are shown in Figure 4.6.
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Figure 4.5: Model simulation for a single representative patient. The base-10
log of the leukemia and immune cell populations, in cells/mL, are plotted as a
function of time, in months. The thick solid line represents the total leukemic
population (ytotal = y0 + y1 + y2 + y3), and the thick dashed line represents
the immune cell population (z). The thin solid lines show the immune window
[ymin, ymax] = [10
4.58, 105.44] cells/mL. For the first twenty months, the patient’s
leukemia load decreases monotonically, while the immune cells begin to expand.
The leukemic population enters the immune window at around month 7. The
immune cells mount an attack starting around month 18. This first attack results
in the minimum leukemia load achieved during therapy, at around 104 cells/mL.
The immune cells drive the leukemia load below the immune window, allow-
ing the leukemic population to partially recover. The two populations oscillate
with decreasing amplitudes as they approach their equilibrium concentrations of
(ytotal, z) = (10
4.61, 105.85) cells/mL. This simulation corresponds to the plot in
Figure 4.3(d) (patient 4 in Table 4.2).
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Patient inh1 inh2 dz µ ymin ymax
1 9.944 131.016 0.187 4.021 · 10−8 6.001 · 104 1.754 · 105
2 33.268 148.517 0.131 1.515 · 10−8 1.443 · 104 4.521 · 104
3 4.612 92.3215 0.031 9.964 · 10−7 4.994 · 104 5.598 · 105
4 1.456 545.150 0.099 1.504 · 10−8 3.765 · 104 2.759 · 105
5 1.872 1700.274 0.128 3.082 · 10−7 2.482 · 104 6.513 · 104
6 9.652 43.752 0.238 1.350 · 10−7 1.050 · 105 8.637 · 105
7 5.771 155.963 0.019 4.057 · 10−8 4.846 · 104 3.695 · 105
8 591.591 14.568 0.040 2.371 · 10−7 3.132 · 103 2.228 · 104
9 486.315 226.000 0.075 2.879 · 10−8 3.536 · 102 1.684 · 103
10 50.988 79.645 0.005 1.271 · 10−6 1.182 · 103 5.482 · 104
11 30.208 359.979 0.371 2.263 · 10−7 4.959 · 103 1.353 · 104
12 1.5201 265.6435 0.015 2.748 · 10−8 2.031 · 104 9.352 · 105
Table 4.2: Parameter values for patients 1-6 were used to produce Figure 3, while parameter
values for patients 7-12 were used to produce Figure 4. Here, ymin and ymax can be used to
obtain immune parameters ϵ = 1/(yminymax) and α = (ymin + ymax)ϵdz.




Mean 1.132 2.487 0.099 -7.047 3.970 5.024 1.053
STD 0.830 0.754 0.097 0.636 0.888 0.804 0.499
Max 2.772 3.880 0.371 -5.896 5.483 6.024 2.006
Min 0.024 1.073 0.005 -7.954 2.548 3.226 0.197
Table 4.3: Summary of parameter values used in our model simulations. Of the 65 IM
patients who do not relapse, develop drug resistance, or progress, 22 change their IM dose
during therapy. An additional 6 patients have non-international standard (non-IS) mea-
surements, and 11 patients have five or fewer measurements. We focus on the remaining
25 patients and present the mean, standard deviation, maximum, and minimum parameter
values.
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Figure 4.6: Quality of the fit as a function of a pair of parameters, for a single
representative patient. This is the same patient whose simulation is shown in
Figures 4.3(d) and 4.5 (patient 4 in Table 4.2). Red dots indicate worse fits,
and dark blue dots indicate better fits. Here, we only show simulations that
resulted in a total cost of less than 10, where cost is the squared log-distance
between the patient data and model simulation. (a) log(inh2) vs. log(inh1).
For this patient inhibition values satisfying log(inh1inh2) in [2, 4] were tested.
These two parameters are strongly related to the quality of the fit. (b) log(µ)
vs. dz. These two parameters seem to be the least important, as it is difficult
to see any correlation between the fit and either of these parameters. (c) ymax
vs. ymin. There is a definite relationship between the fit and these two variables.
The worse fits tend to be in the upper left corner, while the better fits tend to be
in the lower right corner. The parameters ymax and ymin determine the immune
window and therefore affect the timing and magnitude of the autologous immune
response.
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The parameter values in Table 4.3 suggest that IM alone results in a 3.5-log decrease
in the total leukemia load, on average (STD: 0.786, max: 5.158, min: 2.426). This effect is
divided into a 2.5-log decrease in the proliferation of mature cells and a 1-log decrease in
the proliferation of progenitors. Each patient’s immune window covers approximately one
order of magnitude of leukemic populations, generally falling between 102.5 cells/mL and 106
cells/mL. We assume an initial mature leukemic population of 1.5 · 108 cells/mL. Thus, IM
must decrease the leukemia load by several orders of magnitude before the leukemia enters
the immune window and an immune response is initiated. After the leukemic population
enters this window, the leukemia and immune populations oscillate, with the amplitude of
oscillations decreasing over time.
4.4 Discussion
Despite the success of IM and other TKI therapies, many questions about the underly-
ing mechanisms of action remain. Mathematical modeling is a complementary tool to clinical
and experimental data that can help us understand these mechanisms. Several mathematical
modeling groups have already studied various aspects of CML. We briefly review some of
these contributions but note that a more thorough review can be found in Chapter 2.
Michor et al. [65] constructed an ODE model of CML that divides leukemic cells
into stem cells, progenitors, differentiated cells, and terminally differentiated cells. Upon
analyzing patients’ initial responses to IM therapy, they found that IM often leads to biphasic
exponential declines in the leukemic cell populations. Their modeling results suggested that
the first, steeper decline represents the action of IM on the differentiated leukemic cell
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population, while the second, slower decline represents an effect on the leukemic progenitors.
They later hypothesized that long-term therapy leads to a triphasic exponential decline,
where the third decline may represent an effect on immature leukemic cells and possibly
leukemic stem cells [98].
On the other hand, Roeder et al. [85] developed an agent-based model of CML that
divides leukemic stem cells into cycling and quiescent compartments. In their model, IM
results in the degradation and inhibition of cycling leukemic stem cells while having no direct
effect on quiescent leukemic stem cells. They interpreted the biphasic exponential decline
as an initial degradation effect, followed by a change in the regulatory response of leukemic
stem cells which produces the second decline. A similar interpretation to the biphasic decline
is proposed in [48].
Although these modeling frameworks are capable of reproducing the dynamics of some
patients during therapy, both are limited to those who show a monotonic decline in their
leukemic burdens. Neither model includes a mechanism that would allow patients to show
oscillations in leukemia load. However, in our data, we found that many patients who respond
well to IM and achieve long-term remissions exhibit increases in leukemic burden. The fact
that the Michor and Roeder models are unable to reproduce such oscillations suggests that
there may be (an) additional mechanism(s) that contribute(s) to patients’ dynamics during
therapy.
Motivated by this, we developed a mathematical model that integrates CML and an
autologous immune response. As previously discussed in Section 1.3, there is strong evidence
that the immune system plays a role in the dynamics of CML. In our modeling framework, we
defined an immune window, or a range of leukemic loads that will provoke a strong autologous
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Figure 4.7: Comparison of the model with and without an autologous immune
response. Patients 4 and 10 from Table 4.2 are shown in (a) and (b), respectively.
The dots represent patient data, the solid lines represent fits for the model with
an immune response, and the dashed lines represent fits for the model without an
immune system (set z(0) = 0 and sz = 0). The dotted line in (a) approximates
the minimum leukemic level that is detectable by RT-PCR. Dots along this line
represent zero measurements, meaning CML cells were not detected. For simu-
lations without an immune response, inh1 = 17.140 and inh2 = 239.330 in (a),
and inh1 = 37.393 and inh2 = 299.235 in (b). All other parameters, besides sz
and z(0), are set to those given in Table 4.1. Only the model with an autologous
immune response is able to produce the non-monotonicity seen in both patients’
BCR-ABL ratios.
immune response. At diagnosis, the leukemic load is above this window, and the large
leukemic population is able to partially or fully suppress the autologous immune system’s
response to CML. IM therapy generally reduces a patient’s leukemic load by several orders
of magnitude, representing a significant reduction in immunosuppression. We hypothesize
that IM may drive the leukemic population into the immune window, allowing a patient’s
autologous immune system to mount a response to CML.
In our model, oscillations in leukemic load occur after the leukemia enters the immune
window. Without the autologous immune response, our model produces monotonically de-
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creasing cancer loads, as seen in Figure 4.7. Once the autologous immune cells have expanded
sufficiently, they attack the residual leukemic population. This first attack by the autologous
immune system results in the minimum detectable leukemic load achieved during IM therapy.
However, because the leukemia is driven below the immune window, the patient’s immune
cell population begins to contract. If the leukemia is not eradicated, it is able to rebound,
until it reenters the immune window, thus stimulating another weaker immune response.
The immune and leukemic cell populations continue to oscillate in this way, with the ampli-
tude of these oscillations decreasing over time. Eventually, the oscillations dampen, and an
equilibrium is achieved between the leukemic and autologous immune cells. Our modeling
results suggest that oscillations in BCR-ABL ratio during therapy may be partially explained
by the patient’s autologous immune response to the residual CML population.
Moreover, the oscillations may be a signature of the autologous immune response, that
can be used to characterize a patient’s individual immune system. This result is reminiscent
of previous tumor-immune models, e.g. Kuznetsov et al. [50].
Based on a patient’s data over the course of TKI therapy, we determine their im-
mune profile in the context of our model. Each patient’s immune profile is different, as
demonstrated by differences in the immune windows and in the timing and magnitude of the
autologous immune response to CML. Our modeling framework provides a potential tool to
help quantify these differences, which may play a significant role in designing personalized
therapies or combination therapies aimed at further reducing or eradicating the residual
CML burden. This framework will serve as a basis for future studies of treatment cessation
and personalized combination therapies consisting of TKIs and immunotherapy.
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4.5 Conclusion
The potentially significant role of the immune system in the dynamics of IM ther-
apy suggests that immunotherapy may help to eliminate the residual leukemic burden. In
our simulations, when IM therapy drives the leukemia into the immune window, an ini-
tially strong immune response occurs that weakens over time. Eventually, the immune cell
population contracts, allowing the leukemia to partially recover. A combination of IM and
immunotherapy may help to maintain a strong immune response, to prevent such a recovery
in the leukemic population. As suggested in [43], carefully-timed vaccines may stimulate the
patient’s immune system when the residual CML burden is no longer sufficient. A sustained
immune response may result in a further decrease of the leukemic population and may even
drive the leukemia to extinction. An optimal vaccine schedule would depend heavily on each
patient’s immune profile, and our model offers a tool for characterizing this.
Although we focus on the autologous immune response as a possible explanation of
the oscillations that occur during IM therapy, many other factors may contribute to this
behavior. The microenvironment of the leukemic cells is known to have a strong influence on
both healthy and leukemic cells [51,63], but is not included in our model. Additionally, we do
not account for patients who do not properly or regularly take their drugs, which is known to
be an important factor [62]. Moreover, for simplicity, we do not distinguish between various
subtypes of immune cells, each of which may interact and play different roles in CML. Our
model can be expanded in order to achieve a more accurate representation of the autologous
immune response to CML. We leave this for a future work.
Still, the oscillations in patients’ leukemic loads suggest an additional mechanism dur-
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ing therapy that has not previously been included in mathematical models. Our modeling
results support the hypothesis that the autologous immune system contributes to the dynam-
ics of IM therapy. If this is the case, our model may serve as a valuable tool for characterizing
a patient’s immune response to CML. This immune profile may then help in designing per-
sonalized combination therapies in order to further control or eliminate the residual leukemic
burden.
4.6 Afterthoughts: An Alternate Mechanistic Model
We also consider the following alternative model of CML and the autologous immune
system, in which the immune-leukemia interactions are based on [50].
ẏ0 = b1y1 − a0y0 − µy0z, (4.3a)
ẏ1 = a0y0 − b1y1 + ry1(1−
y1
K








y2 − d3y3 − µy3z, (4.3d)




This model is similar to Equation (4.1) except in the way in which the immune response is
represented. In the previous model, immunosuppression is incorporated by dividing the mass
action terms representing immune-leukemia interactions (immunostimulation αy3z and the
killing of leukemic cells by immune cells µyiz) by 1+ϵy
2
3. As was previously mentioned, these
terms encode an immune response that is most effective at intermediate levels of leukemic
stimulus. This representation is not motivated by a specific mechanism of immunosuppres-
sion, although we note that these immunosuppression terms are similar to terms found in [61].
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In their model, proliferation rates and renewal fractions are divided by a factor 1+kc6, where
k is a constant, and c6 is the mature blood cell population, in order to incorporate the effect
of a regulatory cytokine. The presence of two regulatory cytokines would lead to division by
a quadratic function of the mature population, producing terms similar to those in Equations
(4.1a)-(4.1e).
In the mechanistic model, there are no terms representing immunosuppression of
the immune-leukemia interactions. Rather, mature leukemic cells are assumed to have
two contrasting effects on immune cells, as seen in the last two terms of Equation (4.3e).
The Michaelis-Menten term (αy3z/(1 + ϵy3)) represents the stimulation of immune cells by
leukemic cells, with maximum rate α2ϵ
−1 and Michaelis constant ϵ−1. The mass action term
(α2y3z) represents the killing of immune cells by leukemic cells, at a rate α2.
Although the two models of CML and the autologous immune system represent immune-
leukemia interactions differently, they are qualitatively very similar and produce similar fits,
as seen in Figures 4.8 and 4.9. The mechanistic model does, however, introduce an additional
parameter α2, and this model seems to be stiff. For convenience, although both models seem
plausible and it may be difficult to exclude either until further information about the nature
of immunosuppression in CML is known, we choose to focus on our original model given by
Equations (4.1a)-(4.1e).
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Figure 4.8: Fits of our two models to patient data. Dots indicate patient data.
Fits of our original model (Equations (4.1a)-(4.1e)) are shown in red. These
fits are obtained as described in Section 4.2. Fits to the alternative mechanistic
model (Equations (4.3a)-(4.3e)) are shown in blue. These fits are obtained using
a similar strategy, with one additional immune parameter α2. The two models
produce comparable fits.
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Figure 4.9: Six additional fits of both models to patient data. Fits of our original
model (Equations (4.1a)-(4.1e)) are shown in red, while fits to the alternative
mechanistic model (Equations (4.3a)-(4.3e)) are shown in blue. Dots indicate
patient data. A dotted line approximates the lowest detectable BCR-ABL ratio.
Dots along this line indicate zero measurements. Again, the two models produce
comparable fits.
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Chapter 5: Analysis of a Simplified Model of CML and the Immune System
The analysis that follows is the result of a collaboration with Apollos Besse, a graduate
student and member of Inria and the University of Lyon.
5.1 A Simplified Model
We consider the following simplified version of our original model presented in Chapter
4:
ẏ0 = b1y1 − a0y0, (5.1a)
ẏ1 = a0y0 − b1y1 + ry1(1−
y1
K








ż = s− dz + α y2z
1 + ϵy22
. (5.1d)
In contrast to our original model (Equations (4.1a)-(4.1e)), the simplified model includes
only three leukemic subpopulations: quiescent stem cells y0, cycling stem cells y1, and mature
cells y2. We exclude the progenitor compartment in order to make the analysis of the system
more accessible. Our analysis provides insight into the behavior that should be expected
from the full model, although we acknowledge that this simplification may affect the stability
properties of the system.
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We initially include a term d1y1 that represents the natural death of leukemic stem
cells. However, we can incorporate this term into the logistic growth term ry1(1− y1K ) simply
by redefining r and K as rnew = rold − d1 and Knew = rnewrold Kold.
Additionally, we assume that immune cells have the same effect on both leukemic stem
cells and mature leukemic cells, by setting µ1 = µ2 := µ and ϵ1 = ϵ2. We arrive at the
following system:
ẏ0 = b1y1 − a0y0, (5.2a)










ż = s− dz + α y2z
1 + ϵy22
. (5.2d)
Because all coefficients in Equations (5.2a)-(5.2d) are positive, the populations must remain
nonnegative and satisfy
y1 ≤ K y2 ≤
a1K
d2
:=M z ≥ s
d
.
5.2 Steady States of the Simplified System
We want to determine the steady states of the system given by Equations (5.2a)-(5.2d)















We will call the interval [ymin, ymax] an immune window. If we define Y = (ymin + ymax)/2,
then ϵ = (yminymax)
−1 and α = 2Y ϵd.
Proposition 5.2.1 There is one healthy equilibrium given by (0, 0, 0, s
d


















dϵy22 − αy2 + d
=
s(1 + ϵy22)
dϵ(y2 − ymin)(y2 − ymax)
,
where y2 is a positive root of the polynomial






X)(1 + ϵX2). (5.3)
These roots lie outside [ymin, ymax].
Proof The equilibria can be found by setting Equations (5.2a)-(5.2d) to zero.











0 = s− dz + α y2z
1 + ϵy22
.
The healthy equilibrium (0, 0, 0, s
d
) clearly satisfies these equations. We now search for equi-
libria such that yi > 0 for i = 0, 1, 2. Then, ẏ0 = 0 iff y0 =
b1y1
a0
















By multiplying Equation (5.4a) by y2, we can set it equal to Equation (5.4b) and solve for



















dϵy22 − αy2 + d
. (5.5c)
When α2 ≥ 4ϵd2, we can rewrite the equation for z with respect to ymin and ymax as follows.
z =
s(1 + ϵy22)
dϵ(y2 − ymin)(y2 − ymax)
.
Thus, z > 0 iff either y2 < ymin or y2 > ymax. That is, equilibrium values for y2 must lie
outside the immune window.
We have found y0, y1, and z with respect to y2, so all that remains is to find the


























It follows that y2 must satisfy



















where the second equality comes from the fact that 1
ϵ
= yminymax. Thus, P (0) < 0 iff
µs < rd. Later, we will find that we are interested primarily in the case when µs < rd.
When P (0) < 0, since P (ymin) > 0, it follows that there is a zero of P on (0, ymin).
Additionally, provided ymin < M , P is positive on the intervals [ymin,min{ymax,M}] and
[max{ymax,M},∞). When ymin < ymax < M , if we can find a value y∗2 ∈ (ymax,M) such
that P (y∗2) < 0, then it will follow that there are at least two additional roots of P , one in
(ymax, y
∗
2) and another in (y
∗
2,M).
Since all steady states (y1, y2, z) must satisfy y2 < M , it follows that:
• If ymax ≥M , then we expect roots only on (0, ymin).
• If ymax < M , then we expect roots on (0, ymin) and possibly (ymax,M).





), an intermediate one (y0,int, y1,int, y2,int ≈ ymax, zint), and a low one
(y0,low, y1,low, y2,low ≈ ymin, zlow).
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5.3 The Healthy Steady State
The healthy equilibrium (0, 0, 0, s
d
) represents the case when there are no leukemic cells.
We can linearize the system about this point to obtain the following.
ẏ0 = −a0y0 + b1y1, (5.6a)











y2 − dz. (5.6d)
Thus, the matrix of this system is
A =

−a0 b1 0 0
a0 −b1 + r − µsd 0 0






This matrix has a characteristic polynomial
χA(X) = (X + d)(X + d2 +
µs
d
)[(X + b1 − r +
µs
d
)(X + a0)− a0b1]
= (X + d)(X + d2 +
µs
d
)(X2 + (a0 + b1 − r +
µs
d
)X + (−r + µs
d
)).
Define f(X) = X2+(a0+b1−r+ µsd )X+(−r+
µs
d
). It is clear that λ1 = −d and λ2 = −d2− µsd
are two eigenvalues of A. The other two eigenvalues are the roots of f . Suppose rd < µs.
Then f(0) > 0 and f ′(0) > 0, so the remaining two eigenvalues have negative real part,
making the healthy equilibrium stable. If rd > µs, then f(0) < 0, so it follows that one
of the remaining eigenvalues is real and positive, making this equilibrium unstable. We are
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primarily interested in the latter case, so for the remainder of this discussion, we will assume
that rd > µs. Recall that this assumption implies that P (0) < 0, so P will have a zero on
(0, ymin).
5.4 Steady States Without Suppression of Activated Immune Cells
The polynomial P given in Equation (5.3) has degree five. We can simplify the problem
by adjusting our immunosuppression parameters ϵ1 and ϵ in one of two ways.
• Set ϵ1 = 0. That is, assume that immunosuppression only affects the activation and
expansion of immune cells but does not affect an activated immune cell’s efficacy at
killing leukemic cells.
• Set ϵ1 = ϵ. That is, assume that immunosuppression affects the activation and efficacy
of immune cells equally.
Both assumptions reduce P to a degree three polynomial. For now, we consider the first
case, as parameter estimates suggest that this is reasonable.
By setting ϵ1 = 0, we arrive at the following model
ẏ0 = b1y1 − a0y0, (5.7a)




ẏ2 = a1y1 − d2y2 − µy2z, (5.7c)










X)(1 + ϵX2). (5.8)
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We can expand this polynomial in the following way:
P (X) = X3(1 +
µs
dd2

























= X3ω+ −X2(ymin + ymax +Mω−)
+X(Mymin +Mymax + yminymaxω+)−Myminymaxω−.
Here, ω+ = 1+
µs
dd2
and ω− = 1− µsrd . Since we want the healthy equilibrium to be unstable,
it follows that rd > µs and therefore ω− > 0. Therefore, P has alternating signs, so by
Descartes’ rule of signs, P cannot have any negative roots. Because P has odd degree, it
must therefore have either 1 or 3 real positive roots.












− 1) + 2ω+
ω−




then P has three positive roots, one in (0, ymin) and two in (ymax,M).
Proof Since P (0) < 0 < P (ymin), P has a root on (0, ymin). If M satisfies Equation (5.9),
then M > ymax. We will now show that P has two roots on (ymax,M) by finding a value of
X ∈ (ymax,M) such that P (X) < 0. Since P (ymax) > 0 and P (M) > 0 the result will follow
immediately.
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We begin by searching for X = cM for a positive constant c. Consider P (cM):
P (cM) = (cM)3ω+ − (cM)2(ymin + ymax +Mω−)
+cM(Mymin +Mymax + yminymaxω+)−Myminymaxω−
= c2M3(cω+ − ω−) + cM2(ymin(1− c) + ymax(1− c))
+Myminymax(cω+ − ω−)
= M [(c2M2 + yminymax)(cω+ − ω−) +M(ymin + ymax)c(1− c)].
If we assume that c < ω−
ω+
< 1, then we can produce the following upper bound:
P (cM) < M [c2M2(cω+ − ω−) +M(ymin + ymax)c(1− c)]
< cM2[cM(cω+ − ω−) + (ymin + ymax)(1− c)]
< cM2[c2Mω+− c(Mω− + 2Y ) + 2Y ].
Define Q(c) = c2Mω+ − c(Mω− + 2Y ) + 2Y . Then, Q is a degree two polynomial with
determinant
∆ = (Mω− + 2Y )
2 − 4(Mω+)(2Y )
= M2ω2− + 4MY ω−(1− 2
ω+
ω−
) + 4Y 2
= (Mω− + 2Y (1− 2
ω+
ω−
))2 − 4Y 2((1− 2ω+
ω−
)2 − 1)
= (Mω− − 2Y (2
ω+
ω−

















− 1) + 2ω+
ω−
− 1).














− 1) + 2ω+
ω−
− 1) > 1.
Therefore M > 2Y
ω−
which implies that c < ω−
ω+
< 1. Thus,







Since c < 1 we know that cM ∈ (0,M). However, it is not clear whether cM ∈ (0, ymin) or
cM ∈ (ymax,M) (we know that P is positive in [ymin, ymax]). By ensuring that
M >
ymin(2ω+ − 1)− ymax
ω−
,
it follows that cM > ymin and hence cM ∈ (ymax,M). We conclude that P has two roots on
(ymax,M).
When ymin < M < ymax, the theorem does not apply, and there will be one equilibrium







The bound given by Equation (5.9) is not necessarily the minimum lower bound. How-
ever, this proposition does provide a sufficient condition that guarantees three equilibria.
5.5 Stability Analysis
We will now shift our attention to the stability of the fixed points of the system given
by Equations (5.7a)-(5.7d). To approach this problem, we further simplify our model by no







ẏ2 = a1y1 − d2y2 − µy2z, (5.10b)
ż = s− dz + α y2z
1 + ϵy22
. (5.10c)
We note that all of the analysis up to this point holds for this new system. That is,
removing the quiescent stem cell compartment does not affect the number of steady states
or the stability of the healthy equilibrium. Although it is possible that this simplification may
(in some cases) affect the stability of the other fixed points, this analysis provides valuable
insight into the original system.
We start with the low equilibrium (ȳ1, ȳ2, z̄) satisfying ȳ2 ∈ (0, ymin). In general, the
matrix of the system (5.10a)-(5.10c) linearized about (ȳ1, ȳ2, z̄) is given by
B =

r − 2 r
K
ȳ1 − µz̄ 0 −µȳ1




















We wish to prove that the low equilibrium is stable. To do this, we will make use of the
following Lemma.
Lemma 5.5.1 Consider a polynomial P (X) = X3 + aX2 + bX + c with positive coefficients
a, b, and c. If ab > c, then the dominant root of P has negative real part.
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Proof Because P has positive coefficients, it cannot have positive real roots by Descartes’
rule of signs. Also, since P (0) = c > 0, P must have at least one real negative root λ. The
remaining two roots are either negative real or complex. If they are negative, then we are
done. If the roots are complex, then we wish to show that the real part is negative. We can
factor P as
P (X) = (X − λ)(X2 + (a+ λ)X + (b+ aλ+ λ2)).
Denote the complex roots as z and z̄. Then since
X2 + (a+ λ)X + (b+ aλ+ λ2) = (X − z)(X − z̄),
then it follows that
a+ λ = −(z + z̄) = −2Re z,
b+ aλ+ λ2 = zz̄ = (Re z)2 + (Im z)2.
Now, we observe that P (−a) = −ab + c < 0 since ab > c. Since λ is the only negative root
of P , it must be that −a < λ. Hence, Re z = −a+λ
2
< 0.
Proposition 5.5.2 The low equilibrium (ȳ1, ȳ2, z̄) satisfying ȳ2 ∈ (0, ymin) is asymptotically
stable.
Proof We first observe that the all terms in Equation (5.11) have sign independent of the
fixed point coordinates, except αz̄ 1−ϵȳ2
2
(1+ϵȳ22)2
. Define E = 1−ϵȳ2
2
(1+ϵȳ22)2




2 < 1, so E > 0. (If ȳ2 > ymax, then E < 0.)
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Consider the characteristic polynomial χB of B.











































+ µαȳ2z̄E) + a1µαȳ2z̄E))
































= r + d2.
Since ȳ2 ∈ (0, ymin), E > 0. Thus, χB has positive coefficients. We would like to apply
the previous lemma to complete our proof. Thus, we consider



















































































By the previous lemma, χB has a dominant root with negative real part, so the dominant
eigenvalue of B has negative real part. We conclude that the low equilibrium is asymptoti-
cally stable.
The low equilibrium should be attracting for sufficiently close initial conditions. How-
ever, the basin of attraction is so small that almost all solutions converge to the large
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equilibrium. Thus, a successful treatment should either expand the basin of attraction of
the low equilibrium or eliminate the larger equilibria.
5.5.1 Special Case: sz = 0
We consider the case when sz = 0 because it allows us to fully classify the equilibria.
These classifications provide insights about the stability of the equilibria when sz is small.










We will first assume that α2 > 4ϵd2 and ymax < M . Then we can rewrite ż as
ż =
−dϵ(y − ymin)(y − ymax)
1 + ϵy22
z.
It follows that ż = 0 iff z = 0, y2 = ymin, or y2 = ymax. The first case produces the equilibria
(0, 0, 0) and (K,M, 0). The other two cases produce the equilibria (y1(ymin), ymin, z(ymin))














Thus, we have four equilibria. Since s = 0, the condition for the healthy equilibrium (0, 0, 0)
to be unstable reduces to rd > 0. Hence, the healthy equilibrium is always unstable. Further,
by Proposition 5.5.2, (y1(ymin), ymin, z(ymin)) is asymptotically stable. We wish to classify
the remaining two equilibria.
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First, consider (y1(ymax), ymax, z(ymax)). The matrix of the system linearized about


















































Since ȳ2 = ymax, it follows that 1− ϵȳ22 < 0, so χC(0) < 0. Therefore, χC must have at least
one real positive root, so (y1(ymax), ymax, z(ymax)) is unstable.
The last equilibrium (K,M, 0) represents the case when the leukemic population fully
overcomes and suppresses the immune system. The matrix of the linearized system about





0 0 −d+ αM
1+ϵM2
 . (5.14)
The characteristic polynomial is




so the eigenvalues of (5.14) are λ1 = −r, λ2 = −d2, and λ3 = αM1+ϵM2 − d. Since M > ymax,
it follows that all three eigenvalues are negative, so (K,M, 0) is a stable node.
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K Stem cell carrying capacity 4.2872r/(r + d1)
d1 Stem cell death rate 0.00225
a1 Differentiation and expansion rate 2.16 · 106
d2 Mature cell death rate 0.06
s Immune cell source term 120 * d
y1(0) Initial stem cell concentration K
y2(0) Initial mature cell concentration a1K/d2
z(0) Initial immune concentration s/d
Table 5.1: Universal parameters and initial conditions for our simplified model.
When α2 < 4ϵd2, no immune window exists, and ż < 0 whenever z > 0. Hence, the
only positive equilibrium is (K,M, 0), and it is stable, by a similar argument to the one given
above. A saddle-node bifurcation occurs when α2 = 4ϵd2, provided ymin = ymax < M .
When M < ymin, the only positive equilibrium is (K,M, 0), and it is stable. Lastly,
when ymin < M < ymax, there is only one positive equilibrium: (y1(ymin), ymin, z(ymin)). By
Proposition 5.5.2, it is stable.
Recall that treatment has the effect of decreasing M . As M approaches ymax from
above, the two equilibria (K,M, 0) and (y1(ymax), ymax, z(ymax)) approach one another.
There is a saddle-node bifurcation at M = ymax, after which (M < ymax), both equilib-
ria are eliminated.
5.6 Numerical Simulations
Fits of our simplified model (Equations (5.10a)-(5.10c)) to data of two patients are
shown in Figure 5.1. The universal parameters and initial conditions used in Figure 5.1 are
provided in Table 5.1.
As in Chapter 4, IM is assumed to decrease the leukemic cells’ differentiation rate a1
by a factor inh to a′1 =
a1
inh
. The treatment parameter, inh, and immune parameters, µ,
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Figure 5.1: We fit two representative patients to our simplified model given in
Equations (5.10a)-(5.10c). Patient data is represented by dots, and our fits are
shown as solid lines. The dashed line approximates the detection threshold, or
the lowest detectable leukemia level. Dots along this line represent zero mea-
surements, which indicate BCR-ABL ratios below the detection threshold. (a)
This data corresponds to patient 4 in Table 4.2. The following patient-specific
parameter values were used: d = 0.127, µ = 10−8.18, ymin = 10
4.50, ymax = 10
5.34,
inh = 102.85, r = 0.0134. (b) This patient proved difficult to fit when varying
only the drug and immune parameters. By varying both r and d, the model
is able to reproduce the slower fluctuations present in the data. The following
parameters were used: d = 0.006, µ = 10−9.25, ymin = 10
2.97, ymax = 10
5.26,
inh = 103.64, and r = 0.0276.
α, d, and ϵ, are allowed to vary between patients. We additionally allow r to vary, as it
characterizes the aggressiveness of the leukemic clone. Varying both r and d allows us to
reproduce slower fluctuations, as seen in Figure 5.1(b).
We now consider the effect of the treatment parameter inh on the number and sta-
bility of the steady states. Our results for the patient in Figure 5.1(a) are shown in Figure
5.2. For small values of inh, four equilibria exist: the healthy equilibrium (0, 0, s
d
) (dark
blue), the low equilibrium (y1,low, y2,low ≈ ymax, zlow) (green), the intermediate equilibrium
(y1,int, y2,int ≈ ymax, zint) (red), and the high equilibrium near (K,M, sd) (light blue). The
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Figure 5.2: The steady states and their stability are plotted as functions of inh.
For each value of inh, there are at most four equilibria: the healthy equilibrium
(0, 0, s
d
) represented by dark blue, the low equilibrium (y1,low, y2,low ≈ ymax, zlow)
represented in green, the intermediate equilibrium (y1,int, y2,int ≈ ymax, zint) rep-
resented in red, and the high equilibrium near (K,M, s
d
) represented in light
blue. However, for large values of inh, the middle and high steady states are
eliminated. Circles mark the inh value (707.95) used in our model simulation
shown in Figure 5.1(a). (a) Stem cell concentration y1 is plotted against inh. In-
terestingly, y1,low and y1,int are increasing functions of inh. (b) Mature leukemic
concentration y2 is plotted against inh. A saddle-node bifurcation occurs when
inh ≈ 593, and the low and high equilibria are eliminated. (c) Immune cell con-
centration z is plotted against inh. (d) The real part of the dominant eigenvalue
is plotted against inh. When these values are above (below) the dashed line
λ = 0, the corresponding fixed points are unstable (stable). Hence, we see that
the healthy and intermediate steady states are always unstable, while the low
and high equilibria are always stable.
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healthy and intermediate equilibria are always unstable, as indicated by negative real parts
of the dominant eigenvalues in Figure 5.2(d). The low and high equilibria are stable. These
stability results are in agreement with our analysis in the previous sections.
Although both the low and high equilibria are stable, the high equilibrium has a larger
basin of attraction, so most simulations converge to this equilibrium rather than the low
equilibrium. Since we would like treatment to decrease the leukemic population significantly,
one possible strategy is to drive the leukemic population toward the low equilibrium, either
by expanding the basin of attraction of the low equilibrium or by eliminating the high
equilibrium. As we will see, the latter occurs in our simulation.
As inh increases, the mature leukemic concentration of the high equilibrium y2,high
decreases. When inh ≈ 593, there is a saddle-node bifurcation. The high stable equilibrium
collides with the unstable intermediate equilibrium, and both are eliminated for larger values
of inh. This result also supports our analysis. In our model simulation shown in Figure
5.1(a), inh = 707.95. This value is indicated in Figure 5.2 with circles. Thus, during
IM therapy, only the stable low equilibrium and unstable healthy equilibrium exist, so the
patient converges to the low equilibrium.
Interestingly, in Figure 5.2(a), we see that the steady state leukemic stem cell con-
centration is an increasing function of inh. Large values of inh, while effective against the
mature leukemic population, allow a large residual leukemic stem cell population to persist.
As inh increases, the leukemic stem cell concentrations approach the carrying capacity K,
which is approximately marked by the light blue line. A large leukemic stem cell population
increases the risk of resistant subpopulations that could eventually cause relapse. This result
suggests that treatment should achieve an inh value large enough to drive the leukemia to the
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low equilibrium but small enough to prevent a large residual leukemic stem cell population.
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Chapter 6: Applications and Extensions
In this section, we apply our modeling framework developed in Chapter 4 to studying
various aspects of CML. We first present fits of our model to patients treated with second-
generation TKIs nilotinib and dasatinib. We then expand our model in order to study drug
resistance, treatment cessation, and combination therapy.
6.1 Dynamics During Therapy with Second-Generation TKIs
A group of 46 patients with CML was monitored at the Centre Hospitaller Lyon Sudd
during therapy with second-generation TKIs. One group of 21 patients was treated with
dasatinib (100 gm daily), while the other 25 patients were treated with nilotinib (600 gm
daily). The BCR-ABL ratios were measured at diagnosis, months 3, 6, 9, and 12, and every
six months thereafter. The average follow-up time for these patients is 25.14 months (range:
2.06 - 62.33), with an average of 6.98 measurements during this time (range: 2 - 14). Six
dasatinib patients change TKIs, one of whose disease progresses. Two nilotinib patients also
change TKIs, both of whose disease progresses.
In comparison to the IM data, the average follow-up time is much shorter. Only seven
patients (4 dasatinib, 3 nilotinib) have at least ten measurements. We chose not to include
any patients taking dasatinib or nilotinib in [17] because of the shorter follow-up times and
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the smaller number of patients per drug. A shorter follow-up time makes it more difficult
to evaluate our model’s ability to fit patients treated with second-generation TKIs. It is
also difficult to classify a patient’s immune response to CML, as such a response during
IM therapy seems to occur only after several months to a few years of therapy. Still, 23 of
the 38 patients who do not relapse and whose disease does not progress show at least one
increase in BCR-ABL ratio during therapy. Thirteen even show increases that are larger
than 0.5-log. Our previous modeling results suggest that these fluctuations may represent a
patient’s immune response to CML.
In order to further investigate this phenomenon, we applied the model in Equations
(4.1a)-(4.1e) to these patients. Fits to patients treated with dasatinib are shown in Figures
6.1(a)-6.1(c), while fits to patients treated with nilotinib are shown in Figures 6.1(d)-6.1(f).
The universal parameter values used in these simulations are the same ones in Table 4.1
of Chapter 4. Patient-specific parameters are given in Table 6.1. These particular patients
were chosen because they have the largest number of measurements. However, we note that
the patients in Figures 6.1(b), 6.1(c), and 6.1(e) change TKIs (at months 20, 28, and 9), and
the patient in Figure 6.1(e) shows disease progression (at month 10). The remaining three
patients have no adverse events.
Patient inh1 inh2 dz µ ymin ymax
1 21.056 349.677 0.119 3.972 · 10−8 1.246 · 104 3.401 · 105
2 40.701 14.192 0.122 1.039 · 10−7 1.481 · 105 3.483 · 105
3 1.122 810.343 0.046 6.314 · 10−7 4.488 · 104 2.291 · 105
4 1.026 11253.417 0.021 1.558 · 10−8 2.309 · 102 2.103 · 104
5 83.619 15.117 0.084 2.488 · 10−7 6.478 · 104 2.016 · 105
6 18.676 161.473 0.047 1.492 · 10−8 1.456 · 104 8.915 · 104
Table 6.1: Patient-specific parameter values for patients shown in Figure 6.1.
Similar to patients treated with IM, patients treated with second-generation TKIs
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Figure 6.1: Fits of the model given in Equations (4.1a)-(4.1e) to patients treated
with second-generation TKIs. Patients were treated with either dasatinib (Fig-
ures 6.1(a)-6.1(c)) or nilotinib (Figures 6.1(d)-6.1(f)). The base-10 log of the
BCR-ABL ratio is plotted against time, in months. Dots represent patient data,
and the solid lines represent the simulations. Dashed lines show the BCR-ABL
ratios that correspond to the ends of immune window, ymin and ymax. Dotted
lines approximate the minimum leukemic level that is detectable by RT-PCR.
Dots along this line represent zero measurements, meaning CML cells were not
detected.
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appear to exhibit three phases of leukemia reduction: a first sharp exponential decline,
a second slower exponential decline, and a period of fluctuations that may be caused by
leukemia-immune interactions. Patients’ immune windows tend to span approximately one
order of magnitude. The patient shown in Figure 6.1(d) has a larger immune window.
Interestingly, our model suggests that this patient’s immune response to CML results in
eradication of the disease. The patient’s BCR-ABL ratio levels off at around 10−7 which
corresponds to a leukemic stem cell concentration of less than one cell. Overall, these fits
to patients’ initial responses to second-generation TKIs suggest that this model is capable
of capturing the dynamics of patients treated with both IM and second-generation TKIs
dasatinib and nilotinib.
6.2 Incorporating Drug Resistance
We study the effects of pre-existing resistant leukemia by incorporating sensitive and





1 + ϵ(x2 + y2)2
, (6.1a)
ẋ2 = axx1 − d2x2 −
µx2z






1 + ϵ(x2 + y2)2
, (6.1c)
ẏ2 = ayy1 − d2y2 −
µy2z
1 + ϵ(x2 + y2)2
, (6.1d)
ż = sz − dzz +
α(x2 + y2)z
1 + ϵ(x2 + y2)2
. (6.1e)
In this model, sensitive leukemic cells x and resistant leukemic cells y are divided into stem
cells (x1 and y1) and mature cells (x2 and y2). For simplicity, we do not further distinguish
between cycling and quiescent leukemic cells nor do we include progenitor compartments.
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Sensitive and resistant cells are described by the same pair of equations, except that their
stem cell carrying capacities K and differentiation rates a may differ. Competition between
sensitive and resistant cells is incorporated at the stem cell level with the terms 1 + x1+y1
Kx
and 1 + x1+y1
Ky
.
Prior to treatment, sensitive and resistant leukemic populations are assigned the same
parameter values. Specifically rx = ry := r, Kx = Ky := K, and ax = ay := a. TKI
therapy is assumed to inhibit the sensitive leukemic population by decreasing its stem cell
carrying capacity to K ′x =
K
inh0
and its differentiation rate to a′x =
a
inh1
. On the other
hand, resistant leukemic cells are assumed to be completely resistant to TKIs, that is, K ′y =
Ky = K and a
′
y = ay = a. Initially, it is assumed that the sensitive population is at its
equilibrium for the system without an immune response or a resistant subpopulation (that
is (x1(0), x2(0)) = (Kx,
axKx
d2
)). A small resistant population is introduced (y1(0), y2(0)) =
(1.6667 · 10−3, 1.6667·10
−3ay
d2
), and immune cells are set to z(0) = sz
dz
.
We consider the effect of inh := inh0inh1 on the time to relapse, which we define as
a BCR-ABL ratio exceeding 1. Figure 6.2 shows the time to relapse as a function of inh.
Figure 6.3 shows simulations of a patient’s BCR-ABL ratio during treatment, for specific
values of inh. It is clear from these figures that time to relapse is a nonmonotone function of
drug inhibition. Specifically, in some cases, increasing the drug’s effect results in an earlier
time to relapse.
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Figure 6.2: Relapse time is plotted as a function of inh = inh0inh1. A relapse
time of zero indicates that the patient’s BCR-ABL ratio never falls below 1 during
therapy. Simulations were run for 20 years. A relapse time of 20 years, therefore,
indicates that the patient does not relapse during simulation. Initially relapse
time is an increasing function of drug time. For larger values of inh, the immune
system plays a significant role, and relapse time becomes a nonmonotone function
of inh. In fact, an inh value that is too large can result in a faster relapse. The
following parameter values are used in these simulations: r = 0.008,K = 41.6667,
a = 2.16 · 105, d2 = 0.06, µ = 10−8, sz = 2.4, dz = 0.02, ymin = 104, ymax = 105,




























Figure 6.3: Simulations of a patient’s BCR-ABL ratio for inh = inh0inh1 = 10
n,
n = 1 (blue), 2 (red), 3 (green), 4 (black), 5 (purple), 6 (light blue). All other
parameters are those given in the caption of Figure 6.2. We see that inh = 104
results in the latest relapse, at about 19 years, which is over four years after the
relapse times when inh = 105 or inh = 106.
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6.3 IM Cessation
We now apply our mathematical model to study the dynamics of IM cessation and the
potential benefits of carefully-timed vaccines. We incorporate vaccine cells v into our model
as follows:

































Here, Equations (6.2a)-(6.2d) are the same as in Equations (4.1a)-(4.1e) in Chapter 4. Equa-
tion (6.2e) is similar to Equation (4.1e), except that the vaccine cells provide an additional
stimulus to the immune cells. We assume that vaccine cells do not contribute to immuno-
suppression, hence they are not included in the denominators. Vaccine cells, which are
represented by Equation (6.2f), are introduced at a rate ϕv(t) and die naturally at a rate dv
and as a result of an immune response at a maximal rate µ and with suppression constant ϵ.
The source term is zero, except for the periods during which the vaccines are administered.
Similar to [43], we assume that each vaccine is delivered over the course of a day.
Treatment cessation is simulated by reducing the inhibition parameters inh1 and inh2
to the values inh′1 and inh
′
2, thus resulting in partially restored proliferative capacities of
leukemic progenitors and mature cells. If we were to assume that the pre-treatment and
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Figure 6.4: Simulation of successful treatment cessation. A patient’s BCR-ABL
ratio (solid line) is shown as a function of time in months. For the first 84
months, the patient is treated with IM therapy (red). At month 84, the patient
stops therapy (blue). Despite having a small residual leukemic population which
initially grows, the patient does not relapse. Rather, treatment cessation results
in an immune response that eliminates the leukemic population. Thus, this
patient will remain in TFR indefinitely. Dotted lines mark the patient’s immune
window. For this simulation, we set dv = 0.35, inh
′
1 = inh1, and inh
′
2 = inh2/10.
All other parameters are those of Patient 12 in Chapter 4.
post-treatment leukemic populations have similar growth rates, then we could set inh′1 =
inh′2 ≈ 1 during treatment cessation. However, as suggested in [97], it is possible that IM
exerts a selective pressure on the leukemic population that may result in post-treatment
cells with less proliferative capacity. We therefore choose inh′1 = inh1 and either inh
′
2 =
inh2/10 or inh2/100. We recall that treatment cessation trials have produced two disparate
results. While 60% of patients relapse within the first six months, 40% achieve durable
TFR. Moreover, in many patients who achieved TFR, residual levels of leukemia persisted.
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In our simulations, the success of treatment cessation depends both on the patient’s immune
profile and the growth kinetics of the post-treatment leukemic population. For a single
representative patient treated with IM (patient 12 in Chapter 4), we simulate treatment
cessation starting at month 84. During treatment, IM is assumed to decrease the proliferation
of progenitors by a factor inh1 = 1.5201 and to decrease the proliferation of mature cells by
a factor inh2 = 265.6435. All other model parameters for this patient are shown in Tables
4.1 and 4.2.
We first consider the case when inh′2 = inh2/10. That is, the proliferative capacity of
leukemic cells is partially restored by treatment cessation. Although the leukemia initially
grows, the patient’s immune system is able to mount an efficient response that eliminates
the residual leukemia. Therefore, this patient remains leukemia-free indefinitely without
resuming IM therapy. This behavior, shown in Figure 6.4, represents the best possible
outcome of treatment cessation. On the other hand, if we assume that the post-treatment
leukemia’s proliferative capacity is almost fully restored, by setting inh′1 = inh1 = 1.5201
and inh′2 = inh2/100 = 2.6564, then the patient relapses shortly after treatment cessation.
In our simulations, we resume IM therapy at month 85, one month after cessation, as this
is a likely first follow-up time during cessation. The results of this unsuccessful treatment
cessation are shown in Figure 6.5(a).
For patients who relapse, we consider a combination of IM therapy and vaccines. The
vaccines are intended to maintain a patient’s immune response to CML when the leukemic
stimulus alone becomes insufficient. This prolonged immune response may result in fur-
ther control or even elimination of the residual leukemia. We therefore construct a vaccine
schedule based on a patient’s individual immune profile and response to IM therapy. For
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Figure 6.5: Residual leukemia can be eliminated by a sequence of vaccines. (a)
This patient is treated with first-line IM and achieved a BCR-ABL ratio around
10−2 (red) during treatment. Treatment cessation (blue) starts at month 84.
The patient relapses within the first month and resumes therapy starting at
month 85 (green). A sequence of seven vaccines during IM therapy results in the
elimination of the leukemic burden. (b) This figure focuses on the time during
which the vaccines are administered. Each vaccine delivers 105 cells/mL over a
one-day period. These cells die at a rate dv = 0.35. The solid red line represents
leukemia, while the thick dotted red line represents immune cells. The black
curve represents vaccine cells, and the immune window is marked by thin dotted
red lines. Each of the seven vaccines boosts the total leukemic concentration
into the immune window, thus sustaining immune cells that would otherwise
contract. (c) The effects of a variable number of vaccines on the mature leukemic
population are shown. Administering as many as six vaccines is insufficient to
eliminate the leukemia. However, applying seven vaccines sustains the immune
response long enough to drive the leukemia to extinction. (d) If we increase the
individual vaccines to 2.5 · 105 cells/mL, then only three vaccines are needed to
cure the patient.
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simplicity, just like in [43], we assume that each vaccine delivers a total of 105 cells/mL
over a period of one day. Using the MATLAB function fminbnd, we optimize the timing of
each vaccine, one at a time. That is, the time of the first vaccine is chosen to minimize the
leukemic concentration following the vaccine. Then, the time of the second vaccine is chosen,
and so on. Although this is a simplification of the full optimization problem in which all
vaccine times are chosen in parallel and doses are allowed to vary, this strategy still produces
successful treatment outcomes in many cases.
As previously mentioned, the patient shown in Figure 6.5(a) relapses within one month
of IM cessation and resumes treatment at month 85. Figure 6.5(c) shows the effects of
administering a variable number of vaccines during IM therapy. Administering up to six
vaccines reduces a patient’s leukemic temporarily below the immune window. However, once
the vaccines are stopped, the leukemia is able to return to its original low-level equilibrium
concentration. A sequence of seven vaccines administered during IM therapy results in the
elimination of the residual leukemia, as shown in Figure 6.5(b). Increasing each vaccine’s
dose to 2.5 · 105 cells/mL decreases the number of vaccines necessary to cure the patient to
three, as seen in Figure 6.5(d).
In summary, our model is able to reproduce a TFR in a patient with a small residual
leukemic population at the time of IM cessation. Surprisingly, our modeling results suggest
that treatment cessation alone may result in the elimination of the residual leukemia that
remains even after several years of IM therapy. As suggested in [97], TFR may be partially
explained by a selection effect caused by long-term IM therapy, resulting in a less aggressive
leukemic clone than the one present at diagnosis. However, we acknowledge that many other
factors may play a role in successful treatment cessation, including a patient’s immune profile
110
(which may be affected by IM), the partial restoration of the microenvironment, or dynamics
at the stem cell level. Our modeling framework offers a quantitative tool for exploring these
factors.
For patients who relapse during IM cessation, we propose a combination therapy that
involves IM and patient-specific, carefully-timed vaccines. Unlike IFNα, which is limited in
may cases due to significant toxicity, vaccines offer a low-risk strategy aimed at boosting a
patient’s immune response to CML. This combination may improve a patient’s likelihood of
achieving a TFR if they stop IM therapy a second time. In some cases, these vaccines may
even result in cancer elimination, thus guaranteeing a durable disease-free state.
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Chapter 7: Conclusion
Thanks to TKI therapy, CML has been transformed into a chronic condition in which
patients’ life expectancies are similar those of their healthy counterparts. TKIs specifically
target the constitutively active tyrosine kinase encoded by the BCR-ABL fusion oncogene, a
mutation that is present in the majority of CML patients and which drives the disease. While
TKIs have significant effects on BCR-ABL+ leukemic cells, they leave healthy cells mostly
intact, in contrast to IFNα which is toxic to all cells. Because of their superior outcomes and
their limited toxicity, TKIs remain the primary first-line therapy in the treatment of CML.
Despite these improvements, several open questions remain regarding the treatment
of CML. It is unclear whether TKIs alone are capable of eliminating the leukemic burden.
Most CML patients continue TKI therapy indefinitely, which is both expensive and may
compromise a patient’s quality of life. Although many patients respond extremely well to
TKI therapy and achieve deep remissions, most continue to harbor detectable leukemic clones
even after several years of therapy [86]. This may be partially explained by the claim that
quiescent leukemic stem cells are insensitive to TKIs [29, 80]. The extent of the effects of
TKIs on leukemic subpopulations, particularly leukemic stem cells, remains undetermined.
A more complete understanding of their global mechanisms of action would allow us to
identify any limitations of TKI monotherapy and to propose novel combination therapies
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that may be able to target any leukemic subpopulations that are insensitive to TKIs.
Even if TKIs prove incapable of eliminating all leukemic cells, the IM cessation tri-
als [60, 86] have shown that this is not necessary to achieve TFR. These trials found that
patients who respond especially well to TKI therapy may be safely taken off these drugs,
with about 40% achieving durable TFRs that last for many years. Many of these patients
have detectable leukemic populations yet do not relapse. One study [14] detected leukemic
stem cells in patients who had remained in TFR for up to eight years. Given the persistence
of CML during treatment cessation, there must be some alternate mechanism(s) controlling
the residual disease. A better understanding of these mechanisms would help clinicians to
identify the best candidates for treatment cessation.
The IM cessation trials suggest that about 10-15% of patients diagnosed with CML will
achieve TFR. This low percentage motivates the question of how treatment can be improved
to achieve more TFRs. One possible strategy is to modify the inclusion and relapse definitions
used in the trials. In STIM [60] and TWISTER [86], patients were included only if they
had achieved UMRD for the last two years. Relapse was defined as two consecutive positive
measurements (loss of UMRD), where STIM additionally required a 1-log increase between
these two measurements. It is possible that these criteria unnecessarily exclude patients and
may cause others included in the trials to resume treatment before it is needed. Several
recent studies [59, 88, 92] are exploring relaxed criteria, with positive preliminary results.
These new criteria may allow up to 20-25% of CML patients to achieve TFR.
Even with these new inclusion and relapse criteria, many patients will not respond
well enough to TKI monotherapy to become eligible. Combinations of TKIs with IFNα are
being investigated by several groups [32, 72, 78] in order to further control and reduce the
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residual leukemic population. Because IFNα and TKIs have very different mechanisms of
action [96], it is believed that their combination may have a synergistic effect. While TKIs
will likely be responsible for removing the majority of the tumor burden, IFNα may target
leukemic stem cells that would otherwise survive TKI therapy. Still, the long-term benefits
of these combinations are not yet known. Moreover, the optimal scheduling of these two
agents is an open research question that is especially difficult to address strictly through
experimentation.
Mathematical modeling is a complementary tool to experimental and clinical data that
can provide valuable insights into the treatment of CML. In general, mathematical models
can be applied to study the underlying mechanisms driving an observed behavior that are
difficult to access directly through experiments. They provide an inexpensive environment
for testing hypotheses that are too expensive or unethical to study in a clinical setting.
When physical experiments and clinical trials are possible, modeling results can be used to
guide the experimental design, by identifying the most important parameters and the times
at which they should be measured. They can also provide insight into long-term effects
that will not be observable for several years. When combined with experimental and clinical
data, mathematical models can lead to improvements in patient care and well-being, which
I believe is the ultimate goal of mathematics applied to medicine.
Several mathematical modeling groups have studied various aspects of CML, including
hematopoiesis, cancer genesis, treatment, and drug resistance. Michor et al. [65] construct
an ODE model of CML that divides healthy and leukemic cells into four compartments
based on their maturity. Roeder et al. [85] develop an ABM that also divides healthy and
leukemic cells based on maturity but further divides stem cell into cycling and quiescent
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compartments. Both models are able to reproduce the biphasic exponential declines that
characterize many patients’ initial response to IM. In the Michor model, the first steeper
decline is explained by a decrease in the proliferative capacity of differentiated leukemic
cells, while the second slower decline is explained by a similar effect on leukemic progenitors.
The Roeder model attributes this biphasic decline to two effects on cycling leukemic stem
cells: an immediate degradation effect followed by a change in the regulatory response of the
remaining cells. Interestingly, both models initially assume that a subset of leukemic stem
cells is unaffected by IM. In a later paper analyzing patients’ long-term responses to IM
with the Michor model, Tang et al. [98] find that some patients show triphasic exponential
declines. They hypothesize that the third decline may indicate an effect of IM on immature
leukemic cells, possibly leukemic stem cells.
Although both models are able to reproduce the monotonic biphasic and triphasic
declines observed in some CML patients during IM therapy, our patient data indicates that
many patients show nonmonotonic fluctuations in their BCR-ABL ratios. These fluctuations
do not indicate relapse in the majority of cases and seem to be a natural part of the dynamics
during therapy. The fact that neither the Michor model nor the Roeder model can reproduce
these fluctuations suggests that an additional mechanism not included in either plays a
critical role during IM therapy.
We therefore constructed a mathematical model that integrates CML and a patient’s
autologous immune response (see Chapter 4). Our choice to model the autologous immune
response to CML is motivated by clinical evidence that a patient’s immune system plays
a significant role in the dynamics of the disease. Allogeneic bone marrow transplants and
IFNα, two common treatments for CML prior to TKIs, work in part by stimulating an im-
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mune response against CML. IFNα has reemerged as a potential treatment in combination
with TKIs because of the former’s ability to target leukemic stem cells and its immunostim-
ulatory effects. The treatment cessation trials further support a critical role of a patient’s
immune response during TKI therapy. The fact that some patients achieve TFR despite
detectable leukemia suggests that another mechanism, such as the immune system, is con-
trolling the residual disease. This hypothesis is further supported by the observation that
TFR is associated with prior IFNα therapy and higher concentrations and functionality of
NK cells [39, 66, 74, 81], memory CD8+ T cells [102], and CD86+ dendritic cells [11]. Our
model allows us to investigate the effects of an immune response on the dynamics during
TKI therapy.
Our modeling framework divides leukemic cells into quiescent and cycling stem cells,
progenitors, and mature cells. We additionally include a compartment representing immune
cells that are able to detect and eliminate leukemic cells. We encode in our model an immune
response in which small leukemic loads are an insufficient stimulus, while large leukemic loads
suppress the immune system, thereby limiting its response to CML. However, at intermediate
leukemic concentrations, which we call an immune window, a balance between immunostim-
ulation and immunosuppression is achieved, and the autologous immune system is able to
mount an efficient response against CML. This mechanism allowed us to fit our model to
patients showing nonmonotonic variations in leukemic load.
Based on our patient data, modeling results, and analysis, we hypothesize that patients
receiving TKI therapy go through three phases of leukemia reduction. The initial two phases
are similar to the biphasic decline previously described in [65,85]. During this time, because
leukemic loads are still large, the immune system plays a minimal role, and the decline
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in the leukemic population is driven primarily by the drug. However, as a result of the
biphasic decline, the leukemic load may be driven into the immune window, which allows
the immune population to develop an efficient first response, often resulting in a sudden
sharp decline in BCR-ABL ratio. This first response marks the beginning of the third
stage of therapy. The leukemic population is driven below the immune window, causing the
immune population to contract, allowing the leukemia to partially recover. Eventually the
leukemia reenters the immune window, which initiates another weaker immune response.
This process repeats, producing oscillations in the leukemic and immune populations as the
two populations approach equilibrium. It is during this third phase that fluctuations in
BCR-ABL ratio are typically observed.
Our patient data and modeling results suggest that a patient’s autologous immune
system plays a significant role in the dynamics of TKI therapy. Moreover, the fluctuations
that occur following the biphasic exponential decline may be explained by the immune system
and therefore serve as a signature of a patient’s individual immune profile. Our mathematical
model is a potential tool for quantifying such inter-patient differences, in order to design
patient-specific therapies aimed at achieving TFR.
The ability of our modeling framework to reproduce the dynamics of many patients
during IM therapy suggests that it may serve as a valuable tool in studying other aspects of
CML. Our model is able to fit CML patients treated with second-generation TKIs dasatinib
and nilotinib, as shown in Section 6.1. We also include in Sections 6.2 and 6.3 preliminary
results of applying extensions of this model to drug resistance, treatment cessation, and
combination therapy. A more thorough investigation of these topics may require us to add
more biological detail to this model which can be done, for instance, by incorporating variable
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healthy cell populations, distinguishing between immune subtypes, or introducing the effects
of the microenvironment. These directions are left for a future work.
This dissertation is the product of an active collaboration between clinicians, experi-
mentalists, and mathematicians aimed at using adaptive and quantitative tools to improve
patient care. Working directly with clinicians has not only given us access to data but
has allowed us to construct a more realistic mathematical representation of CML through
their feedback. We were then able to apply the model to study clinically-relevant questions.
We believe that an interdisciplinary environment is the ideal setting for studying complex
diseases like CML, as each group offers unique resources, insights, and perspectives. This
project has convinced me that the most efficient path toward advancing our medical knowl-
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